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Genomic insights into bacterial adaptation during infection 
 
Abstract 
Bacteria evolve during the colonization of human hosts, yet little is known about the 
selective pressures and evolutionary forces that shape this evolution. Illumination of these 
processes may inspire new therapeutic directions for combating bacterial infections and 
promoting healthy bacteria-host interactions. The advent of high-throughput sequencing has 
enabled the identification of mutations that occur within the human host, and various tools from 
computational and evolutionary biology can aid in creating biological understanding from these 
mutations. Chapter 1 describes recent progress in understanding within-patient bacterial 
adaption, focusing on insights made from genomic studies.  
Chapters 2 and 3 investigate how the opportunistic pathogen Burkholderia dolosa 
evolves during long term infections of people with cystic fibrosis, studying patients infected 
during the same outbreak in Boston. Chapter 2 reports the genomic sequencing of 112 isolates 
taken from 14 patients over a period a 16 years. Phylogenetic reconstruction identifies a likely 
transmission network between patients and reveals multiple lung-to-blood transmissions during 
disease progression. Seventeen genes underwent parallel evolution in these patients, revealing 
new genes important to bacterial survival in vivo and highlighting the role of a particular oxygen-
dependent gene regulation pathway.  
Chapter 3 studies the co-existing B. dolosa diversity within single sputum samples taken 
from each patient, using both colony re-sequencing and a population deep sequencing approach. 
The intraspecies diversity within each sample is vast and suggests that the diverging lineages co-
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exist for many years within patients. Furthermore, these diverging lineages evolve in under the 
pressure of selection and in parallel, enabling the identification of genes undergoing selection 
from a single clinical sample.    
Chapter 4 describes two ongoing collaborations that extend these approaches to other 
infections, directly addressing the spatial component of bacterial diversification. Chapter 5 
discusses future potential directions and consequences of the further study of bacterial evolution 
within the human body. 
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Chapter 1: 
Genomic insights into bacterial adaptation and 
diversification within the human host (a review of the field) 
Bacteria evolve during the colonization and infection of human hosts, adapting to the host 
environment, immune defenses, and antimicrobial therapy. Identification of the selective forces 
shaping this evolution can inspire new therapeutic directions for combating bacterial infections 
and promoting healthy bacteria-host interactions. Furthermore, an understanding of how bacteria 
diversify as they adapt can illuminate the molecular mechanisms of pathogenesis and is crucial 
for tracking transmission networks. Breakthroughs in DNA sequencing have recently enabled the 
identification of mutations occurring during infection, but parsing biological understanding from 
these mutations can be challenging. During my time in graduate school, significant strides have 
been made by us and others towards understanding genomic bacterial evolution within humans. 
This Chapter reviews approaches and challenges to understanding within-patient bacterial 
evolution, recent findings, and their implications. 
1
 Motivation 
Bacteria evolve rapidly to meet new challenges; in the context of pathogens this poses a 
therapeutic challenge and a threat to human health. The evolution of bacterial lineages into 
important pathogens is a significant global health problem; approximately 160 newly emerging 
infectious diseases caused by bacteria have been discovered in the past 70 years1. Likewise, the 
rapid spread of drug-resistance in established pathogens poses a significant and mounting danger 
to human health2,3. 
  Yet, the potent weapon of genomic evolution holds enormous potential for research. By 
tracking genomic changes that enable a pathogen lineage to thrive within our bodies, we can 
identify its weaknesses and design therapeutic strategies to heighten these challenges. 
Additionally, within-patient bacterial evolution generates diverse lineages that are separated by 
relatively few mutations, enabling straightforward genome-wide association studies for 
identifying the genomic basis of phenotypic changes4,5. Furthermore, we can use these genomic 
breadcrumbs to track the progression and transmission of pathogens throughout the body body6-8.  
With the speed and cost of genomic sequencing already so favorable (a few days and less 
than $30 per genome, including sample preparation) and getting better every year, the potential 
for rapid insight is enormous. The field of genomic within-patient bacterial evolution has been 
slow to grow, with studies of within-patient cancer evolution surprisingly leading the way in 
some cases despite the higher depth of sequencing required9,10. The investigation of within 
patient-evolution has greatly accelerated in recent years; since 2011, over 25 studies across a 
variety of pathogens have compared multiple genomes of the same species from the same 
patient, compared to 7 previously existing studies. The genomic progress towards understanding 
within-patient evolution of Pseudomonas aeruginosa11 and Staphylococcus aureus12 are 
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 described in recent review articles. Here, I focus on the common themes emerging from the 
study of various pathogens—including parallel evolution and diversification—, common 
challenges to studying within-patient evolution across microbes, and the potential of large-scale 
genomic studies for illuminating epidemiology, clinical practice, and basic biology.  
 
Bacterial adaptations during infection 
Any discussion of within-patient evolution must begin with a discussion of cystic fibrosis 
(CF), as so much of what is known about bacterial evolution within the host comes from chronic 
infections of people with this common autosomal recessive disorder. People with CF lack a 
functioning copy of the CFTR chloride channel and have a number of impairments, including 
viscous mucous that is hard to clear and provides a habitat for long-term bacterial infections. 
Infections of people with CF are polymicorbial13,14, but most people with CF become colonized 
by a single dominant strain which persists for decades, providing many opportunities for 
mutation and selection15.  
Adaptive evolution was noticed in P. aeruginosa, the most common CF pathogen, as 
early as the 1960’s. This adaptive evolution was easy to spot—in many patients, colonies 
cultured in a later stage of the infection produced excess alginate, resulting in a very noticeable 
“mucoid” phenotype, whereas P. aeruginosa isolates from earlier on in infection or the 
environment do so at a much lower rate16,17. This change was shown to be genotypic rather than 
phenotypic17, suggesting parallel evolution. Parallel evolution is a strong signature of positive 
selection and remains the dominant marker of within-patient adaptive evolution today.   
Another reason for the emergence of CF infections as a model system is that, unlike 
many other infections in which antibiotic resistance is conferred via acquisition of a horizontally 
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 transferred resistance cassette, these infections primarily acquire resistance through de novo 
mutation. As these infections are often acquired from environmental sources, they commonly 
start out as antibiotic sensitive and later, in a step-wise fashion, acquire the ability to tolerate 
multiple drugs18. For the same reason, there is now a rapidly growing body of work focusing on 
Mycobacterium tuberculosis within-patient evolution. 
Since the 1960’s, a suite of common phenotypic changes have been observed in P. 
aeruginosa during colonization of the CF lung, where later isolates exhibit particular traits more 
often than earlier isolates. Beyond antibiotic resistance and mucoid colonies, other traits 
associated with P. aeruginosa adaptation to the CF lung include changes to the cell envelope, 
loss of motility, and loss of quorum sensing11.  The parallel evolution of these traits in many 
patients suggests that they are adaptive. Many studies have determined the genetic basis and 
biological roles of these phenotypic changes19,20; for example, mucoid phenotypes are associated 
with worse patient outcome17.  
Yet, the story is complicated because genetic investigations have shown that the same 
commonly mutated master regulators control many of these traits11. As a consequence, many 
heavily studied phenotypic transitions may not be directly selected upon.  For example, while 
many studies have attempted to explain the selective pressure driving alginate production17, it is 
possible that alginate production is a pleiotropic effect of selection on a different component of 
bacterial survival in the lung, such as cell wall stress11. Thus, reliance on phenotypic observations 
alone can bias the researcher towards changes that are not directly selected upon and against 
adaptive changes that are not readily visible. In contrast, genomic approaches offer an unbiased 
and rapid approach to identifying the drivers of adaptation within the host. 
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 Whole-genome sequencing reveals genes under parallel evolution  
  With the advances in genome sequencing in the late 2000’s came the ability to identify 
changes during infection on a genome-wide scale, in an unbiased manner. In a 2006 landmark 
study by Smith et al., the whole genomes of two P. aeruginosa isolates taken from the same 
individual, separated by 8 years, were sequenced using shotgun Sanger sequencing21. The authors 
identified 68 mutations separating these isolates, the majority of which caused amino acid 
substitutions or frameshifts. To identify which of these mutations were likely driving the 
adaptation of these infections, they screened pairs of isolates from dozens of other patients for 
mutations in 24 of the candidate genes using targeted Sanger sequencing. This study revealed 
that many of the mutations found were not common across patients, but that some genes were 
mutated in nearly half of the patients’ later isolates. These commonly mutated genes, thereby 
implicated as some of the most significant contributors to P. aeruginosa survival in the body, 
include multidrug efflux genes and a quorum-sensing regulator. 
This approach of comparing the whole genomes of a few isolates, separated by long 
periods of time, from the same individual has been emulated in many studies of various bacteria. 
Multiple P. aeruginosa infections have been tracked using genomic, transcriptomic, and 
proteomic approaches, and both similarities and differences from the genomic trajectory 
observed by Smith et al. have been reported11,19,22,23. A study of Burkholderia pseudomallei 
evolution during long term asymptomatic carriage of one patient demonstrated genome reduction 
in the host enviornment24 and other changes thought to be towards commensalism25. In a unique 
study, Zdziarski et al. tracked evolution of an asymptomatic E. coli therapeutically introduced 
into the bladder of 6 individuals, finding parallel evolution across patients in multiple genes, 
including stress and virulence associated genes. Interestingly, some genes were mutated during 
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 multiple independent introductions of the therapeutic strain into the same individual, but not in 
other patients, suggesting that adaptation can be host-specific26.   
  Since 2011, the dropping cost of whole-genome sequencing has made a new approach 
possible: the simultaneous sequencing of dozens to hundreds of isolates from each species, 
spanning many individuals6,27-32. This large-scale approach enables systematic and 
straightforward diagnosis of adaptive parallel evolution across patients. Particular progress has 
been made in studies that have focused on sets of patients infected with very similar strains, 
simplifying both the identification of mutations (by use of alignment to a single reference 
genome) and interpretation of the mutations found6,28,32. These studies have use standard 
phylogenetic methods to identify which nucleotides are shared by these closely related isolates 
because of common ancestry, and which are due to parallel nucleotide evolution6,28,32. 
The first such study compared the genomes of 112 isolates of Burkholderia dolosa from 
an outbreak among patients with cystic fibrosis, spanning 14 patients during 16 years6 (Chapter 
2). This study identified 21 genes that were mutated multiple times during the outbreak and 17 
genes mutated three or more times. Importantly, the mutation of a gene twice during these 
infections was consistent with a neutral model, and thus only genes mutated three or more times 
were likely adaptive. Consistent with this analysis, genes mutated three or more times had a 
strong enrichment for nonsynonymous mutations (measured by the canonical signature for 
selection, dN/dS, the relative rate of nonsynonymous over synonymous mutations), while genes 
mutated twice or once did not. This approach has also been used by Marvig et al. on an 
transmissible lineage of P. aeruginosa, with surprisingly similar results. More mutations were 
found in this lineage, requiring a higher threshold for parallel evolution of more than 6 mutations 
per gene. Despite this high threshold, they found many genes under parallel evolution. In both of 
6
 these studies, known antibiotic-resistance determinants and virulence factors evolved in parallel, 
but so did many novel genes, including several two-component systems in P. aeruginosa and an 
oxygen-dependent gene regulation system in B. dolosa. The inferred importance of these genes 
to bacterial survival suggests that their further investigation will be important to understand the 
drivers of within-patient evolution and might uncover new therapeutic directions. A third study 
by Golubchik et al. attempted to identify parallel evolution during asymptomatic carriage of S. 
aureus, but did not find any such evidence during across 13 healthy people carrying the same 
clonal complex28. This is consistent with other signals for purifying selection, and may reflect the 
different lifestyle or evolutionary history of these bacteria. 
  The ability to detect parallel evolution has turned out to be a singularly powerful tool for 
identifying adaptive evolution6,32,33, as other signals for targets of selection are not applicable 
given the low number of mutations. This relatively small number of mutations found during 
infection does not provide a strong enough signal for the use of dNdS at the gene level. And 
while a strong positive or negative dNdS has confirmed that certain sets of genes are undergoing 
positive selection6,32, a neutral dNdS should not be taken as evidence of genomic drift. For 
example, in the B. dolosa study mentioned, positive selection on some genes and purifying 
selection on other genes average across the genome to provide neutral signals of dNdS, which is 
in stark contrast to the strong evidence for adaptive evolution 6 (Chapter 2).   
 
Clock-like evolution of bacterial infections 
  These genomic studies have revealed that single nucleotide mutations accumulate within 
patients according to a molecular clock6,26,31,32,34, even as the rate of observed phenotypic change 
slows27. The finding that bacterial lineages accumulate mutations linearly over time despite 
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 varying strength of selective pressures over time is perhaps surprising, but also echoes the 
findings in laboratory evolution experiments35.  The rate of this molecular clock has been 
estimated for various strains using deliberate infections and subsequent tracking26,34, paired 
clinical isolates30,31, and larger collections of isolates taken from the same patient or group of 
patients6,7,36. These studies have provided estimates of the molecular clock for different species 
and lineages, with most being in the range of 0.5-10 per genome per year. These rates are similar 
to those from studies of outbreaks and global transmissions37-39.   
Various approaches can be employed to estimate the rate of the molecular clock, but the 
most common approach is to calculate the slope of the line of the number of mutational events 
versus time of collection. When doing this calculation, it is important that the number of 
mutational events is estimated relative to the most recent common ancestor or outgroup; because 
most within-patient populations diversify as they adapt (more on this later), using the number of 
mutations separating two isolates can overestimate the molecular clock.  
Another important consideration is the role of recombination in supplying new alleles. If 
horizontally acquired genomic segments are treated as de novo mutations, the rate of evolution 
can be vastly overestimated—and the inferred phylogenies will be incorrect. The importance of 
recombination within patients varies widely between organisms, with some organisms, such as 
Mycobacterium tuberculosis, demonstrating no evidence of recombination despite ample study40 
and others, such as Heliobacter pylori and Streptococcus pneumoniae, showing high rates of 
recombination41-43. Comparison of highly sexual strains requires more complex analysis, as each 
isolate genome may have to be assembled separately de novo, whole-genome alignment must be 
performed, and recombination events need to be identified either before or during generation of a 
phylogenetic tree39,42,44.   
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Hypermutation is common during infection 
The rate of the molecular clock can sometimes change within a strain. One common trend 
in within-patient evolution is the emergence of hypermutation phenotypes, with increased 
mutation rates, during infection. Hypermutation is usually caused by a defect in DNA repair; 
these defects in DNA repair hitchhike along for the ride with beneficial mutations directly 
selected upon, which occur more frequently in these backgrounds45,46. Hypermutation has been 
observed frequently in bacteria colonizing the CF lung, including P. aeruginosa47, Haemophilus 
influenzae48, and S. aureues49 and has also been observed in other pathogens, include E. coli 
infecting the urinary tract46,50.  
Recently, genomic studies have been able to detect hypermutation from sequence alone. 
In the described study by Morvig et al., a number of P. aeruginosa isolates from the DK2 lineage 
had many more mutations than would be predicted based on the sampling time and molecular-
clock estimated from other isolates in the DK2 lineage. Further inspection revealed that only 
these isolates with excess mutations had defects in DNA repair genes, with each isolate’s 
spectrum of mutations matching the known role of these genes in DNA repair32. Similarly, in our 
second study of multiple patients infected during the same B. dolosa outbreak, we observed that 
one patient’s isolates had an excess of transition mutations (purine to purine and pyrimidine to 
pyrimidine) and a corresponding mutation in mismatch repair29 (Chapter 3).  
 
Genomic paths to in vivo antibiotic resistance  
  A complete understanding of antibiotic resistance loci will enable rapid whole-genome 
sequencing  for the diagnosis of antibiotic susceptibilities51 and will provide a deeper 
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 understanding that may one day lead to therapies which will more effectively prevent the spread 
of resistance. Even for M. tuberculosis, an infection in which the genetic causes of antibiotic 
resistance mutations are heavily studied and for which genotypic assays are already clinically 
used to make decision on antimicrobial therapy, studies continue to find new mutations which 
confer resistance to widely-used antibiotics4.  
Comparing the whole-genomes of sensitive and resistance isolates taken from the same 
individual can rapidly identify de novo mutations responsible for resistance. A landmark 2007 
study by Mwangi et al., identified mutations responsible for the sequential emergence of 
resistance to multiple antibiotics during a persistent bloodstream infection with Staphylococcus 
aureus52. Since then, many studies of paired isolates from acute infections have used whole 
genome sequencing to rapidly identify known and novel antibiotic resistance determinants in 
Acinetobacter baumannii, M. tuberculosis, and S. aureus, among others 3-5,53-55. These studies 
have been particularly useful for understanding resistance to last resort drugs like vancomycin, 
colistin, and daptomycin, for which less is known 3,5,52,56,57.  
 Similar approaches can also be used to identify resistance loci across a library of isolates 
taken from chronic infections, provided that resistance genes acquire multiple independent 
mutations across the library. In our studies with B. dolosa, we developed a straightforward 
bacterial genome-wide association study, where we scan each gene for correlations between a 
phenotypic traits and the presence or absence of mutations that gene. Using this approach, we 
verified the known role of gyrA in ciprofloxacin resistance and identified the gene responsible 
for O-antigen variation in this strain6 (Chapter 2). This study did not report any new antibiotic 
resistance determinants, but the approach of comparing very closely related strains has the 
potential to do so simply and affordably.  
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 Beyond identifying mutations conferring resistance, tracking the course of antibiotic 
resistance can reveal new insights into the course of resistance within patients. Snitkin et al. 
additionally tracked the subsequent loss of costly colistin resistance during A. baumannii 
infections of 4 patients. The authors found that in one of these patients, upon removal of drug, A. 
baumannii acquired a mutation that rendered the bacteria less likely to regain colistin resistance3. 
The finding of a mutation that affects future resistance provides hope that we might eventually 
be able to rationally predict and guide the evolution of bacteria during infection to impede 
antibiotic resistance.   
 
 
Bacterial diversification during infection 
  For many infections, mounting evidence suggests that evolutionary dynamics within the 
patient are complex. With few exceptions53, most sequencing studies on sequential isolates from 
individuals have found evidence that later isolates are not always descendants of earlier isolates. 
For example, in Smith et al.’s 2006 study, targeted sequencing of many P. aeruginosa isolated 
during the 8 years separating the sequenced isolates revealed mutations that were not found in 
the terminal isolate. Similar genetic evidence of in vivo diversification (targeted or whole-
genome) has been found in sequential isolates in various infections of the CF lung6,22,27,58, E. coli 
colonization of the bladder26, H. pylori colonization of the gut44, and Mycobacterium tuberculosis 
infections59. These findings are in agreement with earlier studies of these other infections which 
have found coexisting variation of phenotypes and particular genetic loci in single patients29,60-66.   
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 Genomic insights into within-patient diversification 
  More recently, studies have sought to characterize and date the origin of this co-existing 
intrastrain diversity using pooled sequencing and independent sequencing of many multiple 
single colonies cultured from the same time-point29-31,67,68. Studies by Didelot et al. on H. pylori30 
and Harris et al. on S. aureus37 have combined the extent of observed diversity with molecular 
clocks for these species to estimate the time of initial infection, aiding in the detection of 
transmission events. In our second study of B. dolosa evolution, sequencing 29 isolates from the 
same sputum sample and performing pooled sequencing on single samples from 4 other patients, 
we inferred that this diversity can be as old as the initial infection in some patients, but that 
population sweeps may occur in some patients. Furthermore, this study showed that the age of 
co-existing lineages can be inferred from deep sequencing of population samples, without the 
need to know mutational linkage29 (Chapter 3).  
These recent studies of diversity have revealed a rapid way to identify selective pressures. 
In our study of B. dolosa intrapatient diversity, we find many cases where diverging lineages 
underwent parallel evolution within the patient, acquiring independent mutations in the same 
gene. We even find 4 alleles of the same gene coexisting in single sputum sample29 (Chapter 3). 
Remarkably, the only 2 other studies that discuss the identity of mutations separating co-existing 
pathogen lineages also found evidence of parallel evolution within the patient in P. aeruginosa67 
and M. tuberculosis69 infections. Within-patient parallel evolution has also been inferred from 
sequential isolates21,58, adding further evidence that this is a common phenomenon and powerful 
tool for identifying genes under selection in vivo. As many diverging lineages can coexist at 
significantly different frequencies29,63,69, sequencing many isolates or pooled sequencing may be 
important for detecting this signature of selection.  
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   So far, the drivers of this diversification process are unknown, though several hypotheses 
have been proposed. Social cheaters, which gain a growth advantage by not producing a shared 
common good (e.g. quorum sensing mutants, siderophore mutants), may rise in frequency only 
in the presence of cooperators60,70. Similarly, the immune system, phages, or other bacteria 
present during infection might selectively target the most abundant lineages, causing frequency-
dependent selection and impeding dominance of any one lineage in the population71,72. Different 
niches throughout an organ or the body may select for different survival strategies, a notion 
supported by differential representation of phages and microbial species across different parts of 
the lung13,73. Yet, these findings of frequent within-patient parallelism suggest that co-existing 
lineages may be ecologically equivalent; it may be that mutations simply cannot sweep the 
population due to competition between adapted lineages  (clonal interference) and the separation 
of sub-populations across space. The notion that spatial structure may play an important role in 
preventing sweeps in some infections is supported by recent findings that granulomas in M. 
tuberculosis infections are started by single bacteria34. Alternatively, already differentiated 
lineages may evolve in parallel against common selective forces. Further studies, which examine 
the order of mutations acquired in co-existing lineages or identify the location of these different 
strains across the body, will distinguish between these alternative hypotheses.  
 
Implications of within-patient diversity 
  Whatever the origin, the finding that bacteria diversify as they adapt to the human body 
has important implications for clinical diagnosis and research. The full diversity of a pathogen 
population within the patient must be taken into account when performing antibiotic sensitivity 
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 tests, and, depending on the infection, the typical clinical practice of profiling 3-5 colonies may 
not be enough to asses the complete diversity66. 
Additionally, as alluded to above, it is often incorrect to assume that sequential isolates 
obtained during longitudinal studies have descended from one another. Incorrect treatment of an 
earlier isolate as an ancestor, and thus misorientation of the arrow of mutation, can result in 
inflated mutation rates. Furthermore, an incorrect inference about the direction of mutational 
events can mask the role of a mutation in adaptation. For example, in our longitudinal study, we 
found that the ancestor of the B. dolosa outbreak had a stop codon that was reverted 10 
independent times over the course of the outbreak to form a functioning glycosyltransferase 
gene. We found that the full-length gycosyltransferase gene restored O-antigen presentation, 
suggesting an advantage for O-antigen expression in vivo and perhaps a tradeoff during 
transmission6 (Chapter 2), consistent with the observation that O-antigen can inhibit adhesion to 
epithelial cells74. Without proper phylogenetic inference, this stop codon would have likely been 
inferred as the derived allele and the presence of this  polymorphism in the population would 
have been interpreted very differently (Chapter 2). 
  
Diversity and transmission networks 
  Currently, one of the most common uses of bacterial whole genome is to track 
transmission networks across the globe and outbreaks37,75-77. The presence of within-patient 
diversity poses both challenges and opportunities for understanding transmission networks. On 
one hand, the presence of within patient diversity means that the practice of using genomic 
distance between single isolates to infer transmission networks may be seriously flawed78,79. Two 
isolates from the same patient may be separated by more mutations than isolates from different 
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 patients, and which isolate is chosen will drastically change the topology of the network. Still, 
sufficiently diverse genomic sequences can be used to identify that patients are part of the same 
outbreak3,68,77, to rule out potential transmission events25, and to suggest that reinfection is less 
likely than relapse80,81. 
  On the other hand, within-patient diversity, if accounted for, can aid in the identification 
of transmission events. As described above, co-existing diversity can provide a lower bound on 
time since initial infection, provided that patients are initially colonized by a single clone, which 
can be a very powerful tool when combined with epidemiological data28,30,68. Additionally, a 
phylogenetic tree that includes many isolates from each patient in an outbreak and that is rooted 
with an unrelated isolate can help identify transmission events; patients infected by others will 
have their isolates nested inside of another’s diversity6,36,82.  In theory, this and other approaches 
can identify transmission even if patients are initially infected with multiple clones or are 
infected multiple times28,36. However many problems with this approach remain: insufficient time 
to accumulate mutations before transmission may make it impossible to infer the directionality of 
transmission6; frequent parallel evolution at the nucleotide level (relative to generation of other 
mutations) may cause incorrect phylogenetic inferences; and within-patient fixation or 
insufficient sampling can wipe away the diversity needed for proper inference79. 
Despite these caveats, within-patient diversity can aid in our understanding of how 
bacteria spread across organs. In our longitudinal study of B. dolosa, we found that multiple 
isolates in the blood stream of patients were closely related to different lung isolates, suggesting 
multiple transmission events. This suggests that the transmission from lung to blood represented 
a general decline in host function rather than multiple transmission events6 (Chapter 2).  
Similarly, a study of E. coli by Reeves et al. was unable to reveal a particular mutation 
15
 responsible for the transition between asymptomatic colonization and UTI infection, as the same 
genotype was also present during colonization36. In contrast, in a study by Young et al. that 
tracked the progression from S. aureus from carriage to disease, the authors found that all blood 
isolates, including ones take from multiple draws, were identical. Interestingly, this genotype 
was significantly different from previous samples from the nasal passageways, suggesting an 
increased mutation rate or the presence of a distinct unsampled population of S. aureus 
elsewhere in the body7. Surely, similar approaches will be used to address important outstanding 
unknowns in bacterial pathogenesis, such as the directionality of the known transmission 
between the sinuses and lower airways during CF infections83. 
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 Chapter 2: 
Parallel bacterial evolution within multiple patients 
identifies candidate pathogenicity genes1,2 
Bacterial pathogens evolve during the infection of their human hosts1-8, but separating adaptive 
and neutral mutations remains challenging9-11.  Here, we identify bacterial genes under adaptive 
evolution by tracking recurrent patterns of mutations in the same pathogenic strain during the 
infection of multiple patients. We conducted a retrospective study of a Burkholderia dolosa 
outbreak among people with cystic fibrosis, sequencing the genomes of 112 isolates collected 
from 14 individuals over 16 years.  We find that 17 bacterial genes acquired non-synonymous 
mutations in multiple individuals, which indicates parallel adaptive evolution. Mutations in these 
genes illuminate the genetic basis of important pathogenic phenotypes, including antibiotic 
resistance and bacterial membrane composition, and implicate oxygen-dependent gene regulation 
as paramount in lung infections. Several genes have not been previously implicated in 
pathogenesis, suggesting new therapeutic targets. The identification of parallel molecular 
evolution suggests key selection forces acting on pathogens within humans and can help predict 
and prepare for their future evolutionary course.  
                                                
1 Jean-Baptiste Michel and I contributed equally to this work. 
2 This collaborative work was published in the December 2011 issue of Nature Genetics (DOI: 
10.1038/ng.997). The authors are Tami D. Lieberman, Jean-Baptiste Michel, Mythili Aingaran, 
Gail Potter-Bynoe, Damien Roux, Michael R. Davis, Jr., David Skurnik, Nicholas Leiby, John J. 
LiPuma, Joanna B. Goldberg, Alexander J. McAdam, Gregory P. Priebe, and Roy Kishony.  
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 Introduction 
During acute and chronic infections, bacterial pathogens can accumulate mutations that 
allow them to better adapt to their human host1,2, evade the immune response12,13, and become 
more resistant to antibiotic therapy3,4. The spectrum of beneficial mutations that arise during the 
course of a bacterial infection is likely to reflect genetic pathways critical to bacterial 
pathogenesis in vivo, and therefore may inspire new therapeutic directions. Recent advances in 
high-throughput sequencing make it possible to follow the genome evolution of bacterial 
pathogens7-9,14-17, but it is still difficult to tease apart the adaptive driver mutations from the 
neutral passenger mutations that have been fixed by chance9-11. In the laboratory, this is 
addressed by following several populations grown in parallel cultures under identical conditions; 
the adaptive role of mutations is indicated by their recurrence in replicate experiments17-19. In 
natural and clinical environments, such studies are more difficult and have not yet been 
systematically performed on a genome-wide scale. As a result, global patterns of adaptive 
evolution that underlie bacterial pathogenesis in humans are not well characterized.  
Here, we systematically identify recurrent patterns of evolution implicated in 
pathogenesis by comparing the genetic adaptation of a single bacterial strain in multiple human 
subjects during the spread of an epidemic. The airways of people with cystic fibrosis (CF, a 
lethal genetic disorder) are particularly prone to long-term bacterial infections. Most individuals 
with CF become colonized by a dominant bacterial strain that persists for many years20, allowing 
significant time for genetic adaption2. In the 1990s, a small epidemic of Burkholderia dolosa – a 
rare CF pathogen21,22 that can be transmitted from person to person23 – broke out among 
individuals with CF in Boston24,25. A total of 39 individuals were infected with B. dolosa (Figure 
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 2.1a); and all were followed in a Boston hospital, where bacteria isolated during normal care 
were routinely frozen.  
 
Results 
We conducted a retrospective study of 112 B. dolosa isolates from 14 individuals with 
Cystic Fibrosis from this epidemic outbreak – including the first infected subject in the Boston 
area (patient zero) – over the course of 16 years (Figure 2.1b and Table S1.1). During this period, 
five of these individuals received a lung transplant, and eight died. Most of the 112 isolates were 
recovered from the subjects’ airways; a few were recovered from the blood of subjects with 
bacteremia. This collection covers the epidemic with high temporal resolution and enables us to 
study the parallel evolution of the same strain in multiple individuals (Figure S1.1).  
We sequenced the whole-genome of these 112 B. dolosa isolates on an Illumina GAIIx 
sequencer (75bp single-end reads, average read depth 37x; Figure S1.2) and aligned the reads 
onto a B. dolosa reference genome26. We focused our analysis on SNPs; although structural 
variants and mobile elements may also be important, they are beyond the scope of this study. Our 
analysis identified 492 polymorphic loci. These mutations accumulated at a steady rate of ~2 
SNP/year (r=0.79) (Fig. 1c), with no discernible difference between subjects (Figure S1.3). This 
rate of mutation accumulation in the presence of selection within the human body is consistent 
with bacterial mutation fixation rates reported in long-term human infections2,27. The steady 
accumulation of mutations generated enough genetic diversity to resolve evolutionary 
relationships between isolates, which were investigated through the creation of a maximum-
likelihood phylogenetic tree (Figure 2.2a).  
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Figure 2.1. Whole-genome sequencing of 112 Burkholderia dolosa isolates recovered from 
14 epidemic patients indicates steady accumulation of mutations over years. (a) An 
epidemic of B. dolosa spread to 39 people with cystic fibrosis over decades (circles). Time of 
first attested infection for each patient is indicated in years since the collection of an isolate from 
patient zero (labeled ‘A’). We studied retrospectively a cohort of 14 patients from this epidemic 
(gray circles, and labels). (b) The genomes of 112 bacterial isolates were sequenced (diamonds; 
each horizontal line corresponds to a patient). Isolates were recovered over time from the 
patients’ airways (blue), bloodstream (red) or other body compartments (for instance tissue 
obtained during surgery; orange). (c) The number of SNPs between each isolate and the outgroup 
is plotted as a function of time (years since first isolate). Linear fit is plotted (slope = 2.1 
mutations fixed per year). 
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Figure 2.1. Whole-genome sequencing of 112 Burkholderia dolosa isolates recovered from 
14 epidemic patients indicates steady accumulation of mutations over years (Continued).  
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Figure 2.2. Bacterial phylogeny reveals a likely network of transmission between patients, 
and between organs. (a) The maximum-likelihood phylogenetic tree is displayed (SNP scale 
shown). The 112 isolates are indicated by thin dashed lines colored according to patient, and 
labeled according to patient and time (e.g., ‘C-14-5’ was recovered from patient C, fourteen 
years and five months after the first isolate). Blood isolates are indicated by a dollar sign, and 
isolates with the same patient and date are distinguished by letters. The last common ancestor 
(LCA) of isolates from the same patient is represented as a circle of the appropriate color and 
label. Colored backgrounds indicate patient-specific genetic fingerprints. Patients B, C, E, and F 
share the same LCA (white background). (b) Phylogeny between the inferred LCAs suggests a 
likely network of infection between patients (arrows). Dashed arrows indicate less certainty 
(fewer than 3 isolates). (c), Phylogeny between blood and lung isolates recovered from the same 
patient evidences the transmission of multiple clones to the bloodstream during bacteremia 
(multiple arrows, patients N and K).  
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Figure 2.2. Bacterial phylogeny reveals a likely network of transmission between patients, 
and between organs (Continued) 
 At the epidemic level, the phylogeny suggests a network of transmission between 
subjects. Isolates from the same subject tend to form genetically related clusters in the phylogeny 
(Figure 2.2a, Figure S1.3). These clusters define subject-specific genetic fingerprints, from 
which transmission history can be inferred. We constructed the last common ancestor (LCA) for 
each subject’s set of isolates, which bears the subject-specific fingerprints. The phylogenetic 
relationships between these inferred strains indicated the likely network of transmissions among 
the 14 subjects (Figure 2.2b). Because these data account for only 14 of the 39 subjects in this 
epidemic, we cannot determine whether transmission occurred directly from one subject to 
another, or indirectly through a subject not in our study, via a healthcare worker, or through a 
medical device. Nevertheless, this analysis shows that this specific epidemic was transmitted 
through several people during its spread and demonstrates the strength of the approach in 
identifying the infection network of an epidemic.  
At the level of individual subjects, the phylogenetic analysis evidenced the transfer of 
multiple B. dolosa clones to the subject’s bloodstream during bacteremia. We examined isolates 
from the three subjects for whom we obtained more than one blood isolate (subjects H, K, and 
N). In two of these individuals, we found pairs of blood isolates that evolved from distinct lung 
isolates (Figure 2.2c), which is inconsistent with the transmission of a single clone from lungs to 
blood (Figure S1.4a). This evidence for multiclonal transmission is consistent either with a 
punctuated transmission of multiple clones from the genetically diverse lung28-31 (Figure S1.4b), 
or with multiple transmissions occurring over time. These different possibilities would lead to 
recommendations for distinct therapeutic actions: whereas a lung transplant might be effective in 
preventing the continuous leak of bacteria through lesions of the lung, it would not block the 
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 proliferation of bacteria already within the bloodstream. This analysis thus brings into focus 
unresolved questions about the mechanistic basis of bacteremia.    
Finally, we investigated evolution at the gene level. We looked for genetic correlates of 
known pathogenic phenotypes. We first assayed resistance to ciprofloxacin, a fluoroquinolone 
frequently prescribed to CF subjects (Figure 2.3a). Resistance among the 112 isolates varied over 
two orders of magnitudes (Figure S1.5a). We scored each gene for correlation between the 
presence of mutations and drug resistance (Figure 2.3a, inset). This genome-wide association 
study implicated a single gene in the phenotype, BDAG_02180, homolog to Escherichia coli 
gyrA. All the genotypes associated with resistance had nonsynonymous mutations in T83 or D87, 
known for their role in fluoroquinolone resistance4,32,33. Mutations in these residues occurred in 
six subjects. In each case, phylogenetic analysis indicated that mutations were independently 
acquired within the subject, after initial infection (Figure S1.5b). In some cases, we even found 
in the same subject mutations in both residues, each carried by a different isolate. These findings 
support the presence of a strong selective pressure from fluoroquinolones but suggest that there 
are only few genetic paths to resistance in vivo. 
We then focused on a second pathogenic phenotype, the presentation of O-antigen 
repeats in the lipopolysaccharide (LPS) of the bacterium’s outer membrane, known for its 
importance to virulence in related species34-36. We found that some of our isolates present the O-
antigen while others do not (Figure 2.3b). A single nucleotide in the glycosyltransferase gene 
BDAG_02317 correlated exactly with the presentation of O-antigen repeats (Figure 2.3b, inset). 
The ancestral genotype at this locus, a stop codon, corresponds to the absence of O-antigen 
repeats; two different mutations at the same amino acid position – each restoring a full-length 
protein – are associated with presence of the repeats. We confirmed this association 
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Figure 2.3. Pathogenic phenotypes are tied to point mutations in key genes. (a), Minimal 
inhibitory concentration (MIC) of ciprofloxacin for each isolate (vertical bars) is correlated with 
genotypic changes in aminoacids 83 and 87 of BDAG_02180, a homolog to gyrA (bar colors, 
legend). Phylogeny is indicated below as a dendrogram. Inset, p-values for correlation between 
the presence of mutations in each gene and resistance levels (Kendall’s tau). (b), Silver-stained 
gels showing the presence of O-antigen repeats (banded pattern) in the LPS of eight isolates. 
Genotypes of BDAG_02317 (a glycosyltransferase) are shown in the legend. The presentation of 
O-antigen repeats corresponds to a recurrent gain-of-function mutation.   
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 experimentally; we found that complementation with the full-length glycosyltransferase gene 
could restore O-antigen presentation (Figure S1.6a, Supplementary Information 1). Harnessing 
the phylogenetic information, we determined that the last common ancestors of strains from each 
subject presented the truncated genotype. Thus, the gain-of-function mutations occurred in nine 
subjects independently (Figure S1.6b), highlighting the strength of the selective pressure for O-
antigen presentation during the infection. These results identify a previously uncharacterized 
genetic mechanism for O-antigen switching and hint at a tradeoff during person-to-person 
transmission.  
We recognize that the human body challenges bacteria with many selective pressures 
beyond those discussed above. We therefore developed a systematic approach for identifying 
genes under positive selection without prior knowledge of the phenotypes being selected. At the 
genome level, we found no evidence for selection in coding regions (dN/dS~1) and no 
significant intragenic bias (Supplementary Information 1). However, we reasoned that genes 
under selection would be mutated independently in different subjects17-19. We leveraged the 
phylogeny to calculate the number of mutations each gene received, distinguishing genes 
mutated multiple times from those mutated once but appearing in several subjects through the 
expansion of the lineage that carried them. We counted 561 independent mutational events in 
304 genes. Assuming neutral evolution, we would expect that these mutations would distribute 
randomly among the 5,014 B. dolosa genes, and that genes would rarely acquire more than a 
single mutation. Instead, we observed that many more genes than expected contained multiple 
mutations (Figure 2.4a, inset). Seventeen genes were found to have three or more different 
mutations (neutral expectation: ~1, Methods), and four genes had over ten different mutations 
(expected: 0 genes).  
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 To determine whether genes that acquired multiple mutations were under positive selection, or 
were merely sites of mutational bias, we calculated the canonical measure for selection, dN/dS 
(Figure 2.4a). The large subset of 247 genes which contained only one mutation exhibited a 
weak but significant signal for purifying (i.e., negative) selection (dN/dS=0.63, p<10-3, 
Methods). The set of genes with two mutations did not show evidence of selection (dN/dS=1.4, 
CI:0.7-3.1); this set may include a combination of genes that are under some selection and genes 
that fixed two mutations by chance (22 expected under neutral drift; 28 observed). By contrast, 
the 17 genes that acquired three or more mutations received 18 times as many non-synonymous 
mutations as expected by neutral drift, and are under strong positive selection (dN/dS=18, 
CI:4.9-152.7). This suggests that these seventeen genes are not neutral mutational hotspots; they 
are undergoing adaptive evolution under the pressure of natural selection. 
The 17 genes under positive selection (Figure 2.4b, Table S1.2), which are mostly 
conserved across the Burkholderia genus (Figure S1.7), indicate genetic pathways that may be 
involved in pathogenesis. The presence of the two genes previously identified in connection with 
antibiotic resistance and O-antigen presentation (gyrA: 11 mutations; glycosyltransferase wbaD: 
10 mutations) provides a further connection of these genes to pathogenic phenotypes under 
selection. Eleven of the 17 genes belong to functional categories related to pathogenicity: 
membrane synthesis (4 genes, including 2 in LPS biosynthesis), secretion (2), and antibiotic 
resistance (5). The presence of a second glycosyltransferase in the O-antigen cluster (6 
mutations) stresses the importance of this pathway to the disease. Notably, the remaining 6 genes 
had not previously been implicated in pathogenesis of lung infections. Three of these – a 
glucoamylase, a methyltransferase, and a sigma factor – have no well-annotated close homologs 
and their roles in pathogenicity are thus unclear. Another gene trio (homologs of fnr, fixL, and 
36
  
 
 
 
Figure 2.4. Parallel evolution identifies a set of genes under strong selection during 
pathogenesis. (a), Inset, The number of genes that acquired at least m mutations across the 
epidemic is plotted as a function of m (gray bars). This distribution contrasts sharply with the 
distribution expected for neutral evolution (black line). Under neutral evolution, the expectation 
is that only one gene would receive three or more mutations (m>3); instead, we observed 17 such 
genes. Main, The canonical signal for selection (dN/dS) is calculated for these 17 genes (109 
mutations in these 17 genes), the 28 genes with m=2, and the 247 genes with m=1 
(Supplementary Fig. 3 presents the contribution of these mutations to the molecular clock). 
Values of dN/dS greater than 1 indicate positive selection (blue), values smaller than 1 indicate 
purifying selection (red). Error bars indicate 95% CIs. Calculated over all genes without regard 
to m, this analysis would not show a signal for selection. (b), Each one of the 17 genes (rows) 
under positive selection contained an acquired mutated in several patients, signified by squares 
(color intensity indicate the number of mutations observed within this patient). The total number 
of mutations observed within that gene, m, is indicated left. Genes are grouped by biological 
function, and labeled with the annotations of close homologs, and, when available, close 
homolog names. 
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Figure 2.4. Parallel evolution identifies a set of genes under strong selection during 
pathogenesis (Continued). 
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 fixJ), including the gene most mutated gene (BDAG_01161, a homolog of fixL, that had 17 
nonsynonymous mutations), can be linked through homology to oxygen-dependent gene 
regulation37. The large number of mutations in this pathway resonates with reports of lowered 
oxygen tension in CF mucus38 and of ties between oxygen sensing and virulence modulation in 
the gastrointestinal tract39. Homologs of these three genes have been implicated in diverse 
regulatory processes37,39, but their function and the genes they regulate in B. dolosa are currently 
unknown. The identification of 17 B. dolosa genes that underwent selective pressure during 
infection in subjects with cystic fibrosis highlights key pathways involved in pathogenesis and 
may suggest new therapeutic targets for this and other lung infections. 
Tracking the genomic evolution of bacterial pathogens during the infection of their 
human host provides a direct method for observing evolutionary mechanisms in vivo and 
identifying genes central to pathogenesis. This study, which harnesses the combination of high-
throughput sequencing and parallel evolution in the clinical settings, is a step towards a 
comprehensive understanding of genetic adaptation during pathogenesis. Systematically 
identifying selective pressures acting on pathogens within their hosts may help point to new 
therapeutic directions. 
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 Methods 
Study cohort and bacterial isolates,  
An epidemic of Burkholderia dolosa affected 39 patients in the Boston area over twenty 
years25,26. Our cohort includes patient zero, the seven patients for whom bacterial isolates 
recovered from the bloodstream were available, and six patients chosen at random 
(Supplementary Information 1). Samples from these patients were collected during normal care 
(Table S1.1) and frozen. Frozen clinical stocks were streaked on solid media; a single colony 
from each plate was chosen at random and frozen in 15% glycerol to create a working library. 
Time of isolation is reported relative to the collection of an isolate from patient zero (isolate A-0-
0). The use of discarded samples for this study was approved by the institutional review boards 
at Children’s Hospital Boston and Harvard Medical School.  
 
Genome sequencing and SNP calling 
DNA was extracted from single colonies using standard procedures, and multiplexed 
genomic libraries were constructed using the Illumina-compatible NexteraTM DNA Sample Prep 
Kit. Sequencing was performed with 75-bp, single-end reads at a mean read depth of 37x. Reads 
were aligned using the B. dolosa genome AU0158 as a reference, which was isolated from 
patient zero. We used SAMtools 0.1.12a to manipulate consensus sequences and find SNP 
between isolates. Details can be found in the Supplementary Information 1, Table S1.1, Figure 
S1.1, and Figure S1.2. 
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 Rate of evolution 
We estimated the number of SNPs accumulated between each isolate and the outgroup, 
normalizing the SNPs called with confidence to the portion of the genome covered with equally 
high confidence (Supplementary Information 1). These SNPs were found to accumulate at the 
constant rate of 2.1 SNPs/year (Pearson r=0.79), corresponding to a mutation fixation rate of 
3*10-7 per base pair per year. Within patients, mutations accumulate at a similar rate (Figure 
S1.3).  
 
Phylogeny  
The single-nucleotide polymorphisms were used to construct the maximum likelihood 
phylogenetic tree between the 112 isolates (Supplementary Information 1). Our model assumes 
independent evolution at each site, and vertical inheritance. We used the software 
implementation Dnaml (Phylip v3.6939). Different transition-to-transversion ratios produced 
remarkably similar phylogenies; we therefore chose a default model where all mutations were 
equally likely. The LCA for strains from each subject was estimated as the most outward node 
from which all isolates from that patient descended. Each LCA is an inferred genome that 
contains all polymorphisms shared among isolates of that patient.  
 
Ciprofloxacin resistance assay   
Bacterial isolates were grown at 37°C shaking for 24 hours in microtiter plates containing 
LB with logarithmically increasing concentrations of ciprofloxacin (cat # 17850, Sigma-Aldrich, 
USA, Concentrations: 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0 mg/L; we used 10mM hydrochloric acid 
for solubilizing a drug stock of 640 mg/L). The minimum inhibitory concentration (MIC) of an 
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 isolate was estimated as the lowest concentration of ciprofloxacin at which growth was < 10% of 
the maximum growth of that isolate in the absence of drug, as determined by optical density. The 
reported value for each isolate is the logarithmic average of two replicate experiments performed 
on different days. 
 
O-antigen repeat assay 
Twenty isolates (all taken from the airway, including 5 sets of isolates taken from the 
same patient, see Supplementary Information 1) from our library were assayed for O-antigen 
presence. Lipopolysaccharide (LPS) was extracted from each sample as described elsewhere30. 
Extracts were run on SDS-PAGE gels and visualized using Pro-Q Emerald staining. The 
presence of low molecular weight bands on the gel indicated O-antigen repeats. See 
Supplementary Information 1, Table S1.3, and Figure S1.6a for details on O-antigen 
complementation.  
 
Genome-wide association study to detect genetic correlates of assayed pathogenic 
phenotypes 
For each phenotypic assay (MIC to ciprofloxacin; presence/absence of O-antigen 
repeats), and for each gene, we use our 112 strain library to calculate the correlation between the 
value of the phenotype and the presence of SNP (with respect to the LCA of the epidemic). 
Significance was assessed using Kendall’s tau in the case of antibiotic resistance, and with 
Fisher’s exact test in the case of the presentation of O-antigen repeat.   
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 Number of mutations 
The presence of the same SNP in two distinct isolates can signify one of two events: the 
mutation occurred once in an ancestral isolate and was passed on to its descendants, or the 
mutation occurred twice. We resolved this ambiguity by using the phylogenetic tree derived 
above, inferring the genotypes of all internal nodes using parsimonious assumptions. This 
method evidences 20 nucleotide positions that were mutated more than once, including 8 
positions that mutated 3 or more times. We find 8 positions that mutated to 2 different 
nucleotides, and 1 position where all 4 nucleotides were observed. Overall, we count 561 
mutations. For each gene mutated multiple times, we report the number of mutations that each 
patient received in Figure 2.4b. For each nucleotide position within the gene, a mutation is 
counted if there is polymorphism within that patient, or if a mutation first appears in that patient. 
In this way, we do not count inherited mutations, which arose earlier in the epidemic. 
 
Distribution of mutations per gene expected by random drift 
We randomly draw 561 positions in the B. dolosa reference genome, and count the 
distribution of mutations per gene obtained. We repeat this procedure 1000 times and average the 
results.  
 
Estimating the strength of selective pressures  
All but 14 of the 304 genes with polymorphisms correspond to regions of the reference 
genome with no frameshift mutation: we can assess, for these 290 genes, whether mutations 
change the translated aminoacid (nonsynonymous, N) or have no such effect (synonymous, S). 
For any subset of the 290 genes, it is possible to count the observed N and S mutations, and 
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 compare these numbers with those expected under random drift (expected N/S: 2.97; robust to 
transition-to-transversion ratio). The corresponding dN/dS (ratio of substitution rates at 
nonsynonymous and synonymous sites) indicates whether selection might be acting on the group 
of genes under study. Confidence is estimated with Clopper-Pearson binomial confidence 
intervals (95% confidence); one-tailed p-values are computed by simulation.    
 
Manual annotation of genes 
We manually annotated the 17 genes found to be under strong positive selection (Table 
S1.2). Their translated coding sequences were blasted against the ref_seq database using the 
BLASTP algorithm on the NCBI website. Well-annotated proteins (3-4 letter gene name and a 
link to NCBI gene) with high homology (E value < 10-20) were recorded. If the homology 
covered < 95% of the protein sequence, or if there was no such well-annotated protein, the 
protein with highest homology (lowest E value) was recorded. Exceptionally, the gene Shigella 
flexneri fnr gene (not in RefSeq) was included in the annotation list based on 89% homology 
coverage and the presence of two other oxygen-associated genes (fixJ and fixL) among the 17 
genes under strong positive selection.  
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 Chapter 3: 
Genetic variation of a bacterial pathogen within multiple 
patients provides a record of past selective pressures3  
 
Advances in sequencing have enabled the identification of mutations acquired by bacterial 
pathogens during infection1-10. However, it remains unclear whether adaptive mutations fix in the 
population or lead to pathogen diversification within the patient11,12. Here, we study the genotypic 
diversity of Burkholderia dolosa within people with cystic fibrosis by re-sequencing individual 
colonies and whole populations from single sputum samples. Extensive intra-sample diversity 
reveals that mutations rarely fix within a patient's pathogen population—instead, diversifying 
lineages coexist for many years. When strong selection is acting on a gene, multiple adaptive 
mutations arise but neither sweeps to fixation, generating lasting allele diversity that provides a 
recorded signature of past selection. Genes involved in outer-membrane components, iron 
scavenging and antibiotic resistance all showed this signature of within-patient selection. These 
results offer a general and rapid approach for identifying selective pressures acting on a pathogen 
in individual patients based on single clinical samples. 
  
                                                
3 This collaborative work was published in the January 2014 issue of Nature Genetics (DOI: 
10.1038/ng.2848). The authors are Tami D. Lieberman, Kelly B. Flett, Idan Yelin, Thomas R. 
Martin, Alexander J. McAdam, Gregory P. Priebe, and Roy Kishony. 
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 Introduction 
Two opposing models of within-patient bacterial evolution have been proposed: a 
“dominant lineage” model, in which beneficial mutations drive superior lineages to dominate in 
the population, and a “diverse community” model whereby adaptive lineages rise to intermediate 
frequency and coexist with other lineages (Figure 3.1)11-14. The diversity of within-patient 
pathogen populations has major implications for drug treatment and resistance7,15,16, for inferring 
transmission networks8,9,17,18, and for understanding evolutionary processes13,19. Here, to 
distinguish between these models and to understand the sources of genetic diversity, we 
compared the genomes of many bacterial cells of the same strain from the same clinical sample.  
We focused on chronic infections with Burkholderia dolosa, a rare and deadly 
opportunistic pathogen that spread among 39 people in with cystic fibrosis (CF) cared for at a 
single center in Boston starting in the 1990s20,21. The airways of these patients were infected with 
very similar starting strains, and surviving patients have been colonized for many years. A 
previous retrospective study of single-colony isolates revealed specific B. dolosa genes that 
evolved under strong selective pressures during the outbreak8. Now, using sputum samples 
collected during clinical care, we characterize contemporary intraspecies diversity in 5 
individuals from this outbreak who have been infected with B. dolosa since the early 2000’s.  
 
Results  
 We used two genomic approaches, colony re-sequencing (Patient 1) and deep population 
sequencing (Patients 1-5), to identify single nucleotide mutations and their frequencies within 
single sputum samples. In our colony re-sequencing approach, we isolated dozens of colonies 
from a clinical sample and analyzed their genomes individually by alignment of reads to a B. 
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Figure 3.1 Alternative models of within-patient evolution. (a) In the dominant-lineage model 
of within-host evolution, lineages with beneficial mutations sweep to fixation (green lines), 
eliminating their less fit ancestors or other temporarily arising genotypes (dashed lines). In this 
model, most observed mutations will be fixed and polymorphic mutations will be rare, 
representing only recent mutational events (magenta lines). (b) In the diverse community-model, 
lineages coexist and compete for long stretches of time. In this model, most sampled mutations 
will be polymorphic. 
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 dolosa reference genome, AU0158, a strain taken from a different patient in this outbreak. Since 
each colony originates from a single bacterium, this approach is equivalent to comparing 
different bacterial cells from the initial clinical sample. In the population sequencing 
approach22,23, we pooled hundreds of colonies from each clinical sample and sequenced the pool 
with deep coverage (~450x). We then aligned reads to AU0158 and identified fixed mutations, 
appearing in all reads, and polymorphisms, appearing in only a fraction of the reads. To remove 
false positive polymorphic sites caused by systematic sequencing or alignment errors24,25, we 
developed a set of thresholds and statistical tests that reject polymorphic sites where the mutated 
and ancestral reads have significantly different properties22,23 (see Supplementary Information 2). 
We calibrated this approach using an isogenic control for which we expect no polymorphisms. 
For validation, we performed both methods on a single sample from Patient 1, comparing 
diversity among 29 individual colonies to the population sequencing approach (Figure 3.2). The 
population sequencing approach reliably detects polymorphisms where the minor allele 
frequency is larger than 3%, while decreasing the cost and labor required per sample.  
 We found that most mutations that arise during the course of infection do not fix, but 
remain polymorphic within the patient. The colony re-sequencing approach performed for 
Patient 1 revealed 188 mutations occurring in some, but not all, isolates and only 10 mutations 
shared among all isolates. This dominance of polymorphisms, also seen in the population 
sequencing from the same sample, strongly supports the diverse community model (Figure 3.3a-
b). Similarly, for the four other patients, population sequencing on single samples identified a 
preponderance of polymorphisms compared to fixed mutations (≥73% of mutations, Figure 
3.3b). We found these excesses despite the bias to overestimate mutations fixed during infection; 
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 Figure 3.2: Two methods for studying genomic intraspecies diversity. (a) To study within- 
patient evolution, we cultured sputum samples from patients with cystic fibrosis on selective 
media. In the colony re-sequencing approach (solid arrows, performed for one patient), we 
isolated multiple individual colonies from the same single sample, independently called variants 
for each isolate via alignment of reads, and compared variants among the isolates. In the deep 
population sequencing approach (dashed arrow, performed for five patients), we pool hundreds 
of colonies from the same plate and analyze the pool’s genomic DNA. We identified positions on 
the genome where some reads, originating from different colonies on the plate, disagree with an 
inferred ancestral genome (Methods). (b) Allele frequency estimates in the population 
sequencing (y-axis) versus the colony re-sequencing (x-axis) from the same sputum sample (P1) 
for each mutated position. Mutations are classified as either fixed (green circles) or polymorphic 
(magenta circles). Some mutations found in the colony-based approach are sub-threshold in 
frequency or confidence in the pool-based approach (open squares). Slight jitter is added in the X 
and Y locations for each point to improve visibility (up to 2% change). As an example, the insets 
at top and at right display a summary of the raw data at the indicated genomic position. The 
population sequencing (right) at this position shows 70% aligned reads supporting a T (orange) 
and 30% supporting a G (black), consistent with the corresponding number of colonies in the 
individual isolates (22, T; 7, G). Reads from each isolate (top) are mostly of identical calls (all T, 
or all G). Green indicates a single read in one isolate supporting an A, likely a sequencing error. 
For further comparison of the two methods, see Figure S2.7.  
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 Figure 3.2: Two methods for studying genomic intraspecies diversity (Continued). 
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Figure 3.3: Within-patient evolution leads to diversification, not substitution. Mutations 
found in B. dolosa within-patient populations relative to the outgroup are classified as fixed 
(green), or polymorphic (magenta). An excess of polymorphic versus fixed mutations supports 
the diverse-community model over the dominant-lineage model. (a) A maximum-parsimony 
phylogeny of 29 isolates from the same sputum sample (P1) shows the coexistence of diverse 
sub-lineages separated by many single nucleotide mutations accumulating since the last common 
ancestor (LCA) of this patient. Each isolate is represented by a dotted line. (b) The diverse-
community model is also supported by the distribution of allele frequencies from the population 
sequencing in 5 patients’ samples. 
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Figure 3.3: Within-patient evolution leads to diversification, not substitution (Continued). 
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 some fixed mutations in a sputum sample might be polymorphic within the patient’s airways or 
have fixed prior to patient colonization (Figure S2.1).  
 The observed genomic diversity is a reflection of multiple coexisting lineages. 
Investigating the community structure of B. dolosa within Patient 1, we found a deeply branched 
phylogeny with 6 lineages separated by at least 5 lineage-specific mutations (Figure 3.3a). On 
average, pairs of isolates from this sample differed by 26 mutations, and, of all 406 possible 
isolate pairs, only one was identical. Thus, even within a single sputum sample, the population is 
so diverse that full identity between isolates is extremely rare.  
 In one patient (Patient 5), the B. dolosa community had many more mutations than other 
patients’ populations (P < 0.05, Grubbs’ test for outliers). This excess of mutations is due solely 
to increased transitions and not transversions, suggesting hypermutation (Figure S2.2a, P < 0.01, 
Grubbs’ test). A search of the 199 mutated genes unique to Patient 5’s population revealed a 
single mutation involved in DNA repair: a nonsynonymous mutation at a conserved position in 
mutL, defects of which are known to cause excess transitions26 (Figure S2.2b). These excess 
mutations are enriched in synonymous mutations relative to the other patients, further supporting 
hypermutation (P < .001, Figure S2.2c). While hypermutation is a common phenotype in many 
pathogens, hypothesized to accelerate the evolution of antibiotic resistance27-30, it has not been 
previously described in members of the B. cepacia complex31. 
 For how long have these diverging lineages coexisted? The time to the last common 
ancestor (LCA) of each non-hypermutating patient’s population32 can be estimated using the 
number of mutations accumulated since the LCA and the molecular clock  previously measured 
for this outbreak (2.1 SNPs/year8). Given the phylogeny of isolates from Patient 1, we calculated 
the distribution of the number of mutations since the LCA, dLCA, across the population (Figure 
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Figure 3.4: Sublineages coexist within a patient for many years after divergence. (a) A 
histogram of the number (dLCA) of single nucleotide mutations found in isolates from Patient 1, 
relative to their LCA. The black bar indicates the mean value of dLCA across the isolates. (b) The 
value of <dLCA> from the population sequencing data for patients Patients 1 through 4 (Methods). 
In both panels, the axis at top shows the relationship between dLCA and years to LCA, as 
calculated via the molecular clock (2.1 SNPs/yr)8. 
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 3.4a). The mean value of dLCA across isolates, <dLCA>, is 19.6 single nucleotide mutations per 
genome (95% confidence interval, CI = 18.3-20.8), suggesting that the LCA existed 9.3 years 
ago (CI = 8.7-9.9). This places the LCA of the isolates from this sample slightly earlier than the 
first B. dolosa culture from this patient (7.6 years before sample collection), suggesting that the 
B. dolosa population in Patient 1 has been diverging since, or perhaps before, initial colonization. 
While the population sequencing approach cannot provide a distribution of dLCA, due to a lack of 
information regarding linkage between mutations, we can still calculate <dLCA>: it is the sum of 
the polymorphic mutation frequencies (see Supplementary Information 2 for derivation). Using 
this approach, the estimated time to LCA for Patient 1’s population is 7.9 years. This value is 
slightly lower than calculated from the clonal re-sequencing approach, likely due to mutations 
left undetected by our conservative polymorphism caller (see Supplementary Information 2 for 
discussion of error). For Patients 2 and 4, the time to LCA calculated by this population 
sequencing approach is several years less than the time since first positive culture, suggesting 
fixation events sometime during these patients’ histories (Table S2.1). For all these patients, we 
estimate that diverging lineages have coexisted in each of these patients for at least 5 years 
(Figure 3.4b).  
 To explore the drivers of this long-coexisting diversity, we examined the identity of the 
evolving genes. Interestingly, we found that within each sample, several B. dolosa genes carried 
2-4 coexisting polymorphisms (Table S2.2). This clustering is a significant departure from a 
neutral model given the number of mutations and the distribution of gene lengths (Figure 3.5a, P 
< 0.005 for Patients 1-4; Methods). A similar analysis at the operon-level further identified 
several operons enriched for polymorphisms (Table S2.3 and Figure S2.3). An enrichment of 
nonsynonymous mutations in these multi-diverse genes and operons suggests that they are 
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Figure 3.5: Coexistence of alternative adaptive mutations in the same sample highlights 
specific genes as drivers of within-host evolution. (a) Number of multi-diverse genes observed 
in samples from Patients 1-5 (P1-P5, blue bars) relative to a null expectation in which diverse 
sites are randomly distributed across the genome (histogram, 1000 simulations). For P5, the 
number of multi-diverse genes observed is not significant.  (b) The canonical signal for selection, 
dN/dS, across the set of 16 genes and 3 operons showing a multi-diverse signature in at least one 
patient (P1-P4, 21 genes total, blue) versus dNdS across the set of genes not showing this 
signature (black). dN/dS >1 indicates positive selection for amino acid change. Error bars 
indicate 95% CIs. See Online Methods for details on the calculation of dNdS. (c-d) Linkage 
between nearby polymorphisms based on jointly overlapping short reads. Percentages of reads 
supporting the ancestral genotype, each of the single mutants, and the double mutant are plotted. 
No reads supporting the double mutant were found (c, n=524; d, n=415; See Figure S2.5 for 
exception). (e) A network of patients and genes showing a multi-diverse signature at least once 
in P1-P4. A gene is connected to a patient if it was mutated multiple times (solid line), had a 
single polymorphic mutation (dashed lined), or single fixed mutation (dotted line) within that 
patient. Genes closer to the center of the network are mutated in more patients, representing 
common targets of in vivo pathogen selection, while genes connected to single patients may 
indicate patient-specific adaptation. Genes are labeled with their closest homolog and predicted 
biological role. The biological role of rpoD is unclassified because it is recently duplicated in the 
B.  cepacia complex39 (see Supplementary Information 2, Table S2.2). 
 
60
 
Figure 3.5: Coexistence of alternative adaptive mutations in the same sample highlights 
specific genes as drivers of within-host evolution (Continued). 
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 drivers of adaptive change in vivo (dN/dS = 7.0, CI = 2.3-34.9, Figure 3.5b). Polymorphisms are 
thus concentrated within genes undergoing adaptive evolution.  
 To understand why polymorphisms cluster within some genes, we asked if coexisting 
mutations in the same gene appeared in different lineages or were linked in a double mutant. 
Examining the single isolate genomes, we found no isolates with doubly mutated genes (Figure 
S2.4). Similarly, for the population sequencing, in 10 of 11 cases where polymorphic positions 
are close enough on the genome to be covered by the same short sequencing reads, we did not 
find reads that contain both variants (Figure 3.5c, Figure S2.5). In some of these cases, the 
ancestral genotype is completely purged from the population (Figure 3.5d). Thus, diversification 
is driven by multiple adaptive mutations in the same genes evolving in parallel within individual 
patients. 
 These findings provide a new signature of past selective pressures detectable in a single 
clinical sample; the coexistence of multiple polymorphisms within the same gene in a clinical 
sample. Sixteen B. dolosa genes display this multi-diverse signature, including genes with 
homologs involved in outer membrane synthesis, antibiotic resistance, iron scavenging, oxygen 
sensing, amino acid synthesis, lactate utilization, and stress response. Additionally, some genes 
with less characterized biological roles display a multi-diverse signature, including two 
transcriptional regulators with unknown targets in B. dolosa, an uncharacterized glucoamylase, 
and two genes that encode hypothetical proteins (Table S2.2). A similar signature for selection is 
seen in three operons, two involved in lipopolysaccharide transport and one containing a two-
component regulatory system with unknown targets (Table S2.3). Selection on many of these 
elements can be rationalized based on the relevance of their annotated functions to conditions to 
which the bacteria are exposed in the course of the infection. Yet, further investigation will be 
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 required to understand the potential roles of some of these genes in antibiotic resistance, fitness, 
and other aspects of pathogenesis.  
 We found that many of the selective forces acting on the pathogen are the same across 
patients (Figure 3.5e). Often, genes showing a multi-diverse signature for selection in one patient 
also carry mutations in other patients (P < 0.002, hypergeometric test). A prominent example is 
gyrA, a well-studied target of quinolones, which is mutated in all patient populations. Further 
support for commonality in mutational trajectories across patients emerges from a significant 
overlap between this list of 16 multi-diverse genes and 17 genes previously found to be under 
parallel evolution across a larger group of patients, only one of whom (Patient 2) was included in 
both studies (P < 0.001, hypergeometric test). Thus, the study of a single clinical sample can 
provide generalizable lists of selective pressures felt within the human body.  
 Yet, some multi-diverse signatures are patient-specific. A penicillin-binding protein 
(BDAG_01166, homologous to PBP7) has 3 nonsynonymous mutations in Patient 1, but is not 
mutated in other patients. Such patient-specific parallel evolution might reflect patient-specific 
selective pressure or perhaps a fitness benefit dependent upon previously acquired mutations. 
But these hypotheses are hard to test because the genomic target for a selective force might 
include more than one gene. For example, four of the five patients’ populations have a mutation 
in a homolog of the histidine kinase fixL (BDAG_01161, known to be under strong selection in 
these infections8) while the fifth has a mutation in the corresponding response regulator. 
 To investigate the stability of these multi-diverse signatures for selection, we collected a 
second sputum sample 14 days after initial sample collection from Patient 2. Three of the four 
genes with the multi-diverse signature at day 0 show the same pattern at day 14. The absence of 
the signature in the fourth gene at the later time point does not reflect a relaxation in selection for 
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 mutant alleles, but rather incomplete detection of genes under selection; this gene also has 
abundant nonsynonymous mutants at day 14, concentrated at a single nucleotide position (Figure 
S2.6). These results suggest that the multi-diverse signature for selection is relatively stable and 
that multiple sample collections per patient can increase the sensitivity of the detection. 
 
Conclusions  
Our results reject the dominant lineage model of infection, yet demonstrate that these 
diversifying bacteria adapt under the pressure of natural selection. These observations are 
consistent with clonal interference: in large asexual populations, multiple beneficial mutations 
emerge and compete, impeding the ability of these lineages to reach fixation33-35. In addition to 
large population size (108 cells/mL sputum), the branched structure of the airways may further 
hinder the capacity of any adaptive lineage to dominate and fix, and the immune system or 
niche-specific adaptations might directly promote diversity. Diversified by any of these means, 
lineages may then continue to evolve in parallel against common selective forces.  
As B. dolosa adapts to the airways of people with cystic fibrosis, mutations lead to 
diversification rather than fixation and replacement. Though it is possible that adaptive mutations 
will lead to fixation more frequently in other infections, there is evidence that, at least in long-
term colonization, diversity might be common14,36-38. This long-term coexistence of diverse 
lineages records the genomic history of selection on the pathogen within its host. The ability to 
rapidly read off within-patient evolutionary history from the genotypic diversity within a single 
clinical sample may greatly accelerate the ability to survey selective pressures acting on bacterial 
pathogens in vivo – shifting from an epidemic level investigation to a single-patient paradigm.  
  
64
 Methods 
Study cohort and sample collection 
An epidemic clone of B. dolosa infected and colonized 39 individuals with cystic fibrosis 
in the Boston area over a 20-year period21. We studied B. dolosa intrapatient diversity in 5 
surviving individuals still infected with B. dolosa. All subjects were male, had homozygous 
ΔF508 mutations, had not received lung transplants, were between 21 and 35 years of age, and 
had been colonized for between 7 and 10 years at the time of sample collection (see Table S2.1). 
Longitudinal microbial isolates from Patient 2 were also included in a previous retrospective 
study (patient J in reference 8). 
For Patient 1, both the colony re-sequencing and deep population sequencing approaches 
were performed on a single sputum sample (P1). For Patient 2, population deep sequencing was 
performed on each of two sputum samples (P2 and P2T), collected 14 days apart. Between 
collections, Patient 2 was treated for a pulmonary exacerbation, including a change in antibiotic 
regimen, but his condition did not improve and B. dolosa density did not decrease. For Patients 
3-5, population sequencing was performed on a single sputum sample from each patient (P3-P5). 
Expectorated sputum samples were collected at Boston Children’s Hospital after written 
informed consent was obtained under protocols approved by the Institutional Review Boards at 
Boston Children’s Hospital and Harvard Medical School. Samples were liquefied with 
dithiothreitol40 and stored at -80°C in 20% glycerol. B. dolosa was cultured from frozen samples. 
For population sequencing, a plate with 5,000 to 30,000 small colonies was chosen from a serial 
dilution. See Supplementary Information 2 for more details on sample preparation.  
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 Illumina sequencing 
Genomic DNA was extracted using MoBio UltraClean Microbial DNA Isolation Kit per 
the manufacturer’s instructions. Genomic libraries were constructed and barcoded using the 
Illumina-compatible Epicentre Nextera DNA Sample Prep Kit and following manufacturer’s 
instructions (PCR amplification in the Nextera preparation does not introduce false positive 
polymorphisms, see Supplementary Information 2). Genomic libraries were sequenced on the 
Illumina HiSeq 2000 by Partners HealthCare Center for Personalized Genetic Medicine. 
Individual colonies were sequenced using single-end, 50 base-pair (bp) reads and pooled samples 
were sequenced using paired-end, 50bp reads. Reads were aligned to the B. dolosa draft genome 
AU0158 (GenBank accession number AAKY00000000, see URLs), belonging to an isolate 
recovered from patient zero of the outbreak. AU0158 consists of 233 contigs on 3 scaffolds (B. 
dolosa has 3 chromosomes). Standard approaches were used for read filtering and alignment 
(Supplementary Information 2). See Table S2.4 for coverage statistics.  
 
Mutation identification, colony re-sequencing 
An outgroup of 3 outbreak strains (A-0-0, G-9-8, and N-12-6d-$, previously sequenced8) 
was included in the analysis to identify mutations fixed among the 29 isolates from P1. We 
considered genomic positions at which at least one pair of isolates was discordant on the called 
base and both members of the pair had FQ scores less than -40 (FQ scores are produced by 
SAMtools41; lower values indicate agreement amongst reads). Genomic positions for which 
multiple isolates had multiple calls per isolate were discarded (likely duplication not represented 
in the reference). A best call was forced for each isolate (Table S2.5) and the list of concatenated 
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 SNPs was inputted into the dnapars program in PHYLIP v3.6942. The resulting phylogeny was 
visualized the tree using Figtree (Figure 3.3b).  
 
Mutation identification, deep population sequencing 
Fixed mutations within each patient’s population were called using the same procedure as 
individual isolates, with a stricter quality score threshold (FQ < -282). Custom MATLAB scripts 
and SAMtools-produced pileup files were used to summarize all calls and their related quality 
scores at each genomic position (e.g. base quality, mapping quality, tail distance; see 
Supplementary Information 2). Using the isogenic control, multiple isolates from Patient 1, and 
an interactive MATLAB environment that enabled investigation of the raw data, we developed a 
set of filters to identify true-positive polymorphic positions with minor allele frequency above 
3% (Table S2.6). Thresholds were chosen to minimize false positives. See Supplementary 
Information 2 and Figures S2.7-S2.8 for description of filters and sensitivity analysis.  
 
Estimation of <dLCA> 
For the colony-based approach, dLCA was calculated for each isolate as the number of 
mutations received by that isolate normalized by the size of the callable genome. For this 
approach, the callable genome is the set of genomic positions with FQ score < -40. The 
confidence interval for <dLCA> presented for this approach is calculated according to a Poisson 
distribution. For the pool-based approach, <dLCA> was calculated as the sum of the mutation 
frequencies at each polymorphic position called within that population, normalized by the size of 
the callable genome (see Supplementary Information 2). For the pool-based approach, we define 
the callable genome as the set of positions that met the chosen thresholds for coverage, average 
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 base quality, average mapping quality, and average tail distance for each strand, irrespective of 
nucleotide call. See Figure S2.6b and the Supplementary Information 2 for a discussion of 
sources of error in estimating <dLCA> and time to LCA.  
 
Detection of parallel evolution within patients 
We define genes with a multi-diverse signature of selection as genes for which within the 
same sputum sample there were multiple polymorphisms and multiple polymorphisms per 
2000bp (to account for the fact that long genes are more likely to be mutated multiple times by 
chance). To determine whether the number of genes showing this signature was a significant 
departure from what expected in a neutral model, we performed for each sputum sample 1000 
simulations in which we randomly shuffle the polymorphisms found across the callable genome, 
and calculate how many genes show the signature of selection (Figure S2.5a).  
This analysis was repeated at the operon and pathway levels, using the free version FgenesB to 
identify operons and subsystem annotations provided by SEED43 as pathways (see Figure S2.3). 
As in the gene analysis, we considered operons and pathways to have a signature for selection if 
they had both multiple polymorphisms and multiple polymorphisms per 2000 nucleotides with 
the same patient. 
 
dN/dS 
Mutations were classified as nonsynonymous (N) or synonymous (S) according to 
annotations provided in genbank file. For open reading frames in draft genome without a 
provided frame, we used BLAST and RefSeq to identify the most likely reading frame in the 
neighborhood of the found mutations. For each dNdS calculation, we used the particular 
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 spectrum of mutations observed to calculate the expected N/S (e.g. A->C mutations are 10.6 
times more likely to cause an N than G->A mutations). The observed value of N/S was divided 
by this expectation to get dN/dS. Confidence intervals and p-values were calculated according to 
binomial sampling. The dNdS reported Figure 3.5b groups together the mutations found in genes 
and operons under selection; the same calculation for only genes gives a dN/dS of 5.9 (95% CI = 
1.9-29.6). 
 
Parallel evolution across patients 
We used the hypergeometric distribution to assess the significance of overlap between 
gene sets. Of 225 B. dolosa genes mutated in P1-P4, only 16 showed the multi-diverse signature 
for selection within patients and only 29 genes were mutated in multiple of these patients (fixed 
or polymorphic), yet 7 genes are in common between these lists (P=.0015)  Similarly, 13 of these 
225 genes were also found on a list of 17 genes evolved in parallel across patients in a previous 
study8. These 13 genes were enriched in the 16 genes under selection in in this study (5 gene 
overlap, P=.0009). When this analysis was repeated without mutations from P2 (Patient 2 also 
included in retrospective study), 11 of the 189 mutated genes were found in the previous study 
and 13 genes show a multi-diverse signature for selection. The overlap between these lists of 11 
and 13 genes is smaller but still significant (4 genes; P=.0035).  
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 Chapter 4: 
Extension of genomic approaches to study intraspecies 
diversification across space 
 
The finding of sustained intraspecies microbial diversity in Chapter 3 has prompted multiple new 
collaborations. Here, I describe my progress in two of these directions, both of which investigate 
the role of spatial differences in the maintenance of genomic diversity. In the first study, we are 
characterizing Mycobacterium tuberculosis diversity within and between organs, from many 
individuals co-infected with HIV. In the second, we are surveying intraspecies diversity of 
Stenotrophomonas maltophilia in 32 tissue samples taken from the same explanted cystic fibrosis 
lung. These studies will illuminate the mechanistic basis of diversification of these infections, 
point to genes important to survival of these pathogens in different niches within the body, and 
demonstrate that the analytical approaches developed in Chapter 2 and 3 are widely applicable 
methods for gaining insight into microbial pathogens.   
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 Introduction 
Our finding that genotypically diverse descendants of an initial colonizing strain can co-
exist within the airways of a CF patient for long periods of time raises an obvious next 
question—do these different genotypes co-exist in the same microenvironment, or do they 
colonize distinct regions of the airway? A similar, and perhaps orthogonal, unknown is if these 
genotypes have distinct ecological niches. Assessing intraspecies diversity over space can 
address both the spatial and ecological components of within-patient variation. 
Towards this end, I have begun working on two collaborative projects to explore 
intraspecies diversity over space— focusing on Mycobacterium tuberculosis diversity across the 
many body sites of many patients most-mortem and Stenotrophomonas maltophilia diversity at 
finer-resolution within an explanted cystic fibrosis lung. While these two studies (described in 
more detail below), focus on distinct infections and at different levels of spatial resolution, there 
are many commonalities in the approach and questions addressed. 
In both studies, we are sequencing the whole genomes of multiple bacterial isolates from 
each site and identifying mutations relative to a reference genome. Ongoing phylogenetic 
analyses will show the ancestral relationship of strains at different body sites, providing insights 
into transmission routes and migration rates across body sites. The degree of diversity across and 
within sites will have implications for diagnosis and testing, and will inform better models of 
within-patient evolution and the emergence of antibiotic resistance. Integration of location, 
phenotype, and genotype information will illuminate the mechanistic basis of the observed 
genomic differentiation within patients.  
As in the previous chapters, we are also searching for evidence of parallel evolution 
across and within patients in order to identify the selective forces felt by bacteria within the 
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 body. We will use the same phylogenetic approaches performed in Chapter 2 to identify 
nucleotides that evolved in parallel. We will look for parallel evolution within a body site, which 
may suggest site-specific selective forces. By integrating these genomic signals with site-specific 
physiological information, we may be able to better understand the role of these genes to 
bacterial survival in the body.  For example, in the explant lung, co-localization of another 
microbial pathogen (surveyed using 16S profiling) with S. maltophilia genotypes harboring 
mutations in a particular gene might suggest that this gene modulates interspecies interactions. 
 
Within-patient diversity and evolution of Mycobacterium tuberculosis 
We are involved in a collaboration with Theodore Cohen, an epidemiologist and 
associate professor at the Harvard School of Public Health, and others to understand the diversity 
present in individual M. tuberculosis infections and across organs. This ongoing study is based in 
the province of Kwazulu-Natal, South Africa (KZN), where patient-enrollment, sample-
collection, culturing of M. tuberculosis, antibiotic-resistance profiling, and DNA extraction are 
being performed.  In January 2012, I had the opportunity to travel with Dr. Cohen to KZN and 
meet some of our collaborators, including Douglas Wilson, the Head of the Department of 
Medicine at Edendale Hosptial, and Professor Preshnie Moodley at the University KZN. 
 We are comparing M. tuberculosis diversity across the body of many individuals, taking 
multiple biopsies from each individual post-mortem in a limited autopsy. We joined Dr. Cohen 
after he and our other collaborators had already begun on this exciting direction, but before 
sample collection had begun. In this way, we were able to aid in study design to address both 
epidemiological and evolutionary questions about M. tuberculosis diversity. 
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  Initial sample collection is now complete, with 100 autopsies performed. We are focusing 
on co-infections with HIV, in which M. tuberculosis often spreads from the lung to other parts of 
the body. To have the best chance of capturing interstrain and intrastrain diversity, we only 
sampled recently deceased individuals who had been on antitubercular therapy for fewer than 5 
days. We sampled from the respiratory tract (endotracheal aspirate), lung tissue, liver, spleen, 
lymph node, and pleural fluid of each patient, taking multiple biopsies from each location to 
maximize the probability of positive cultures. Biopsies from the lung were cultured 
independently to enable comparison of intra-organ and inter-organ diversity. From other sites, 
biopsies were pooled and cultured by site for practical considerations.  
 Microbial culturing is ongoing for most of these autopsies, and we will analyze the 
microbial diversity for any patient with multiple culture-positive sites (~70%). The DNA from 
each of multiple colonies from culture (up to 15 per site) is being extracted in in the Moodley lab 
and processed in the Kishony lab for sequencing. We have received hundreds of DNA samples 
already and sequenced the DNA 98 colonies. Analysis of these samples is ongoing. Initial 
analysis suggests that single colonies are formed by genetically heterogeneous bacteria, so we 
will need to employ the approaches developed in Chapter 3 to identify de novo mutations.  
 
Intraspecies diversity across an explant cystic fibrosis lung  
 Following our preliminary findings of vast coexisting Burkholderia dolosa genomic 
diversity, together Gregory Priebe, Alexander McAdam, Roy Kishony, pathologist Sara Vargas, 
and infectious disease fellow Dr. Kelly Flett initiated a project at Children’s Hospital to sample 
microbial diversity across an explanted CF lung. Patients with CF occasionally get lung 
transplants, and researchers can sometimes, with the patient or parent’s consent, get access to the 
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 explant lung for study. We devised a plan for sampling many sites from each lung using nearly 
sterile conditions and working within the framework of a standard pathology report. This project 
was then joined by Hattie Chung who is now leading the analysis in the Kishony lab. 
While some sampling of microbial diversity has been performed across lungs these 
studies have been limited for the most part to 16S-profiling of interspecies diversity and have 
focused on the coarse spatial resolution lobes1-3. One notable exception used sequencing of loci 
implicated in antimicrobial resistance to show that M. tuberculosis acquires antibiotic resistance 
independently at different loci within the lung4. To the best of my knowledge, no similar study 
has been conducted with in any other infections or for any organism at the genomic level.  
 It took over two years from receiving initial IRB to receive our first explanted lung. In 
October 2012, we sampled 31 tissue sites, each about a cubic centimeter, from the explanted 
lungs of a patient infected primarily with Stenotrophomonas maltophilia.  We cut cross-sectional 
slices through the lung, sampling from many sites underneath each clean cut (Figure 4.1). 
Sampling sites were chosen to represent different locations and pathologies, including large 
airways, lymph nodes, regions of intense scarring, and healthier tissue. From each site, an 
adjacent tissue sample was sampled for histological staining and pathology reports. Each tissue 
was mechanically homogenized in a special grinding conical tube and frozen in 15% glycerol.  
 We are now analyzing the microbial diversity in this lung, sequencing 24 isolates of S. 
maltophilia from each of 26 sites that grew high densities of this species. We have also used the 
population-sequencing approach developed in Chapter 3 on each sample, but found that colony 
re-sequencing—which is now more affordable—will provide more useful information. 
Preliminary analysis suggests significant S, maltophilia diversity within each site and significant 
differences between sites.    
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Figure 4.1. Sampling of explanted CF lung. We performed sampling procedure of the 
explanted lung in October 2012. Cross sectional cuts were made through the lung, and samples 
were taken from the newly exposed tissue. Two discarded cross sectional pieces are seen in this 
photograph. From each location, two adjacent samples were taken—one for histology and the 
other for microbiology. Each cut was made with a fresh blade, and each sample was taken using 
a new sterile scalpel and forceps. Some cross-contamination may have occurred during slicing; 
to limit this affect the sample for microbiology was taken from underneath the sample for 
histology.  
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 Chapter 5: 
Concluding Remarks 
The Burkholderia dolosa outbreak studied here has proved to be a tractable model system 
for understanding bacterial evolution in vivo and has enabled the development of a powerful 
analytical toolbox. Evidence of parallel evolution and co-existing diversity in other pathogens 
(reviewed in Chapter 1) suggests that the approaches developed here may be widely applicable.  
The applicability of these approaches to acute infections remains to be seen. While 
antibiotic resistance can emerge during acute infections, adaptation against other selective 
pressures faced in the human body has not been shown on this time scale. Should such 
adaptation occur, it is likely that multiple lineages will evolve in parallel and the single-sample 
approach developed in Chapter 3 will identify genes under selection.     
The ability to rapidly identify challenges to survival for each pathogen in vivo, and thus 
potential therapeutic directions, will become of increasing importance as our supply of 
antibiotics continues to dwindle. Furthermore, the potential for the suggested therapies to be 
narrow-spectrum may provide an advantage, as broad-spectrum antibiotics can both disrupt our 
natural flora in dangerous ways and increase the frequency of resistant bacteria. However, an 
important challenge remaining is the development of a roadmap for turning knowledge of 
selective pressures into therapeutic directions. We are currently involved in a collaboration to 
investigate the role of the histidine kinase fixL, the most mutated gene across our studies, and 
oxygen-dependent regulation in B. dolosa pathogenesis with hopes of creating new clinical 
directions. Similar studies are going for P. aeruginosa and other pathogens. 
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 The approaches presented here might also be applied to understanding our commensal 
flora. Each person’s microbiomes contains approximately 1020 nucleotides of DNA (~1014 
bacteria, each with ~106 nucleotides of DNA), and every nucleotide has a probability of about  
10-10 of mutating during each replication event. Therefore, every turnover of our microbiome 
contains about 1010 new mutations upon which selection can act. While the overwhelming 
majority of these mutations will be deleterious, any non-deleterious mutation will enable the 
tracking of commensals within or between body compartments. Furthermore, it is not 
unreasonable to think that members of our microbiome adapt via mutation against challenges 
presented by the particular host or microbial community. The identification of such adaptive 
evolutionary events will add context to species-level microbiome differences and be more 
straightforward to interpret. 
Technical and analytical innovations in the coming years will further accelerate our 
ability to track within-patient evolution and to translate lists of mutations into biological 
understanding. Improvements in single-cell sequencing will facilitate the comparison of genomes 
directly from clinical samples, without any biases introduced by culturing. Increases in scale 
enabled by continuing declines in the cost of sequencing will permit the inference of mutational 
order in parallel lineages and may suggest epistatic interactions between mutations. 
Improvements in the gathering and interpreting of clinical metadata will enable the systematic 
association of evolutionary change with patient outcome. Carefully designed studies leveraging 
these and other innovations will address outstanding questions, including the drivers of within-
patient diversification and the extent to which adaptation is patient-specific.  
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 Appendix 1:  
Supplemental Materials for Parallel bacterial evolution 
within multiple patients identifies candidate pathogenicity 
genes (Chapter 2) 
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Figure S1.1. Distribution of time separating two consecutive isolates from the 
same patient. We plot the number of pairs of isolates taken from the same patient 
within the time windows shown on the x-axis. On average, two consecutive isolates 
were separated by 3.5 months, but in 9 cases isolates were recovered during the same 
week. 
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Figure S1.2. Whole genome sequencing of 112 B. dolosa isolates at 37x depth. a, 
Distribution of the number of 75-nucleotide single end reads obtained per bacterial 
isolate. On average, 4.6 million reads were generated for each isolate. b, Distribution of 
median read depth per position for each isolate. On average, genomes were read to a 
depth of 37x, providing high quality reads for 93% of the genome.
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!!Figure S1.3. Genetic distance between bacterial 
isolates and rate of evolution. a, The rate at which 
bacterial mutations accumulate is consistent across 
patients. We plot the genetic distance of sequenced 
strains to the outgroup as a function of the time of 
isolation (years since first isolate in this study). Isolates 
from the same patient are represented in the same color 
(see legend). Within patients, isolates accumulate 
mutations at a rate similar to that observed for all 112 
isolates. Isolates recovered from the same patient 
are genetically closer.  Distributions of SNP between 
pairs of isolates taken from different patients (B) and 
from the same patient (c). On average, 28 SNPs 
separate two isolates from different patients; isolates 
from the same patient differ by an average 9.5 SNPs. 
Mutations on genes which are not found under 
selection accumulate linearly with time. d We 
exclude from the calculation of genetic distance those 17 
genes under strong selection (which received 3 
mutations or more overall). Mutations accumulate 
linearly with time (Pearson correlation: .83, fixation rate: 
1.9 mutations per year). e, We exclude from the 
calculation of genetic distance the 45 genes which 
received more than one mutation. Mutations accumulate 
linearly with time (Pearson correlation: .79, fixation rate: 
1.6 mutations per year). 
a 
c 
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Figure S1.4. Within-patient bacterial populations. a, b, Models of transmission 
from the lungs to the blood during bacteremia.  Monoclonal transmission (a): a 
single clone from the lung is passed to the bloodstream (single arrow). Multiclonal 
transmission (b): multiple clones are transmitted from the lung to the blood, during one 
or several events (several arrows). c, Phylogenetic analysis provides indirect 
evidence that the B. dolosa population in the CF lung is polymorphic. We 
considered all the triplets of isolates (A,B,C) recovered successively from a patient. For 
each triplet, we asked whether C is genetically closer to A than to B (A-C < B-C), based 
on the phylogenetic tree in Figure 2.2b. A positive answer is not expected if the lung 
was a homogeneous environment for bacteria. We represent in gray the number of 
triplets that are in line with a homogeneous lung and in blue the number of triplets that 
contradict this expectation. We find discordance between phylogeny and time in 37% of 
cases (31 / 85 triplets). This supports a polymorphic model of the lung, where several 
distinct genotypes coexist. 
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Figure S1.5. Resistance to 
ciprofloxacin as a function of 
mutations in BDAG_02180 (gyrA). a, 
We assayed the resistance to 
ciprofloxacin to all 112 isolates 
(precision: 2-fold). We plot on a 
logarithmic scale the average resistance 
of these isolates as a function of the 
mutation observed in BDAG_02180.Thin 
bars indicate the range of MIC observed 
for mutation. The number of isolates 
corresponding to each mutation is as 
follows: wildtype: 88, D87N: 2, T83M: 9, 
D87F: 4, T83K: 9. b, The last common 
ancestors of each patient have drug-
sensitive genotype. We display the 
phylogeny of the 112 strains. Branches 
are colored as a function of the inferred 
genotype in the gene BDAG_02180 at 
codons 83 and 87: black corresponds to 
the wild type—a threonine (T) at position 
83 and aspartate (D) at position 87 (D), 
blue indicates a lysine (K) at position 83, 
orange indicates an methionine (M) at 
position 83, red indicates a asparagine 
(N) at position 87, and purple indicates a 
phenylalanine (F) at position 87. The last 
common ancestors of strains from each 
patient are shown as dots; they are 
colored with their inferred BDAG_02180 
genotype. Even though mutations 
occurred in 6 patients, all the last 
common ancestors bear the wild-type 
BDAG_02180, which is associated with 
gene sensitivity (Figure 3A). This 
indicates that the fluoroquinolone 
resistance evolves within patients, rather 
than being transmitted from patient-to-
patient. 
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Figure S1.6. O-antigen repeats as a function of BDAG_02317. a, Complementation with 
a full-length BDAG_02317 restores O-antigen presentation. Full length 
glycosyltransferase BDAG_02317 was amplified from AU0158 (reference strain) and inserted 
into a plasmid under the control of a constitutive promoter (Supplementary Information 1). 
Transformation of strain A-0-0 with this plasmid restored O-antigen presentation. We note 
variation in O-antigen chain molecular weight, as we had also observed amongst our isolates 
(as seen in Figure 2.3b). b, Most last common ancestors display a truncated 
glycosyltransferase. We display the phylogeny of the 112 strains. Branches are colored as a 
function of the inferred genotype in the gene BDAG_02137 at codon 275 (black: stop codon, 
pink: glutamine , blue: glutamate, gray: unknown). The last common ancestors of strains from 
each patient are shown as dots; they are colored with their inferred BDAG_02137 genotype. 
Even though mutations occurred in 9 patients, all the last common ancestors but one (patient 
D, for whom we sequenced a single isolate) bear the stop codon. We hypothesize that the 
truncated genotype may provide an advantage during patient-to-patient transmission.!
a b 
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Figure S1.7: Most genes under positive selection are conserved across 
Burkholderia. For each gene under positive selection, blastp was used to find the 
nearest homologs in each of the 20 Burkholderia genomic sequences (9 of which are 
also members of the Burkholderia cepacia complex which colonize individuals with CF, 
highlighted in red). For each comparison, a box is drawn if a match was found with an E 
value of less than 10-8, and that box is shaded in according to the percent amino-acid 
identity between the two sequences (see key). B. mallei and B. pseudomallei are 
important pathogens infecting healthy individuals. 
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Figure S1.8. Isolates 
from the outbreak do 
not show significant 
variation in mucoidy. A 
fresh library of isolates 
was obtained by pinning 
from the thawed frozen 
stock into LB and growing 
overnight at 37°C. A 0.3 
microliter aliquot of each 
overnight culture was 
pinned onto omnitrays 
containing YEM agar 
(0.5g Yeast Extract, 4 g 
mannitol, and 15g agar 
per liter) and grown at 
37°C. After one day of 
growth, the plates were 
imaged. The outgroup 
strain, X-3-7, appears 
mucoid (right panel, two 
replicates). All strains from 
the outbreak are 
significantly less mucoid. 
Strains not sequenced for 
this study are indicated 
with “NS.” Not all 
sequenced strains are 
grown because some 
failed to grow on YEM 
agar!
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Table S1.1: 
Burkholderia dolosa isolates used in this study
  
 
 
 
Study name Sample origin SRA Accession 
Patient J    
J-9-11 Airway SRS242466 
J-11-8 Airway SRS242439 
J-11-11 Airway SRS242406 
J-12-4 Airway SRS242440 
J-12-7 Airway SRS242407 
J-13-6a-$  Blood SRS242468 
J-13-6b Airway SRS242467 
J-12-11 Airway SRS242469 
J-14-8 Airway SRS242408 
J-14-2 Airway SRS242470 
Patient K   
K-9-0 Airway SRS242463 
K-10-0 Airway SRS242489 
K-10-1 Airway SRS242432 
K-10-2 Airway SRS242433 
K-10-3a Airway SRS242434 
K-10-7 Airway SRS242435 
K-10-10 Airway SRS242464 
K-11-3a Airway SRS242431 
K-11-3b Airway SRS242436 
K-11-6 Airway SRS242437 
K-12-0a Airway SRS242405 
K-12-0b Airway SRS242438 
K-12-5 Airway SRS242465 
K-12-8a-$  Blood SRS242490 
K-12-9-$  Blood SRS242491 
Patient L 
 
 
L-9-11 Airway SRS242473 
L-10-1 Airway SRS242448 
L-10-2 Airway SRS242449 
L-10-6 Airway SRS242409 
L-10-10 Airway SRS242387 
L-11-3 Airway SRS242388 
L-11-6 Airway SRS242389 
L-11-8 Airway SRS242390 
L-11-11 Airway SRS242391 
L-12-3 Airway SRS242392 
L-12-7 Airway SRS242393 
L-13-0 Airway SRS242394 
L-13-4a-$  Blood SRS242474 
L-13-7 Airway SRS242475 
L-16-0 Airway SRS242476 
Patient M 
 
 
M-9-4 Airway SRS242396 
M-10-6 Airway SRS242397 
M-11-5 Airway SRS242398 
M-12-6 Airway SRS242399 
Patient N 
 
 
N-10-0 Airway SRS242494 
N-10-1 Airway SRS242450 
N-10-5 Airway SRS242451 
N-10-8 Airway SRS242452 
N-10-11 Airway SRS242453 
N-11-2 Airway SRS242454 
N-11-3 Airway SRS242455 
N-11-7 Airway SRS242456 
N-11-9 Airway SRS242457 
N-12-1 Airway SRS242458 
N-12-4a Airway SRS242459 
N-12-4c-$  Blood SRS242496 
N-12-5-$  Blood SRS242429 
N-12-6a Fluid, Right Inferior Hematoma SRS242460 
N-12-6b Pleural fluid SRS242461 
N-12-6c Tissue, Right Lung SRS242462 
N-12-6d-$  Blood SRS242495 
Patient X (outgroup) 
X-3-7 Airway SRS242486 
Study names designate patient and time. For example, 'A-2-4a' was recovered 4 years and 2 months 
after the date of the first isolate in our study, and it was the first isolate recovered from Patient A during 
this month. The second column designates origin of this isolate (blood isolates are also indicated in the 
study name by '$'. The third column indicates the Sequence Read Archive (at The National Center for 
Biotechnology Information, USA) sample number for the publicly available primary sequencing data
Study name Sample origin SRA Accession 
Patient A     
A-0-0 Airway SRS242477 
A-4-2a Airway SRS242478 
A-4-2b Airway SRS242497 
A-5-0a Airway SRS242395 
A-5-0b Airway SRS242479 
Patient B    
B-4-11 Airway SRS242400 
B-7-1 Airway SRS242414 
B-9-1 Airway SRS242401 
B-11-1 Airway SRS242412 
Patient C    
C-4-11 Airway SRS242415 
C-8-0 Airway SRS242484 
C-10-0 Airway SRS242416 
C-12-1 Airway SRS242485 
Patient D    
D-7-10 Airway SRS242441 
Patient E    
E-6-1 Airway SRS242402 
E-8-4 Airway SRS242417 
E-9-5 Airway SRS242428 
E-12-1 Airway SRS242430 
E-13-0 Airway SRS242480 
Patient F    
F-6-9 Airway SRS242481 
F-6-11 Airway SRS242482 
F-7-0a-$  Blood SRS242483 
Patient G    
G-7-5 Airway SRS242403 
G-9-8 Airway SRS242418 
G-9-11a Airway SRS242419 
G-9-11b Airway SRS242487 
G-9-11c Airway SRS242420 
G-10-0a Airway SRS242421 
G-10-0b Airway SRS242422 
G-10-0c Airway SRS242423 
G-10-1b Airway SRS242424 
G-10-2 Airway SRS242488 
G-10-1c-$  Blood SRS242426 
G-10-3 Airway SRS242425 
G-10-6 Airway SRS242427 
G-10-11b Airway SRS242404 
Patient H    
H-8-3 Airway SRS242386 
H-9-5 Airway SRS242410 
H-9-10 Airway SRS242493 
H-9-11 Airway SRS242442 
H-10-1 Airway SRS242443 
H-10-6a Airway SRS242385 
H-10-6b Airway SRS242444 
H-10-10 Airway SRS242445 
H-11-3 Airway SRS242446 
H-12-7 Airway SRS242447 
H-12-10 Airway SRS242472 
H-12-11a-$  Blood SRS242492 
H-13-0b-$  Blood SRS242471 
Patient I 
 
 
I-8-7 Airway SRS242411 
I-9-6 Airway SRS242413 
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 Table S1.2: 
Full annotation and homology for genes under parallel, positive selection used to assess 
biological relevance. !
 
Gene ID Broad annotation 
Number of 
mutations 
Biological 
relevance 
Annotated homologs: organism 
(query coverage) Additional annotation 
 
Genes not previously implicated in pathogenesis 
      
BDAG_01161 PAS 17 Oxygen-related gene regulation fixL: B. rhizoxinica (98) 
Two-component 
system histidine kinase 
BDAG_01160 regulatory protein LuxR 4 Oxygen-related gene regulation fixJ: B. rhizoxinica (99) 
Two-component 
system response 
regulator 
BDAG_04180 transcriptional regulator Crp/Fnr family 3 
Oxygen-related 
gene regulation 
anr: B. multivorans (99), fixK: C. 
crescentus (69)  
      
BDAG_02650 SAM-dependent methyltransferase 8 ? ZP_02908193.1: B. ambifaria (99)  Methyltransferase 
BDAG_04154 DNA-directed RNA polymerase specialized sigma subunit 4 ? 
YP_001116246.1: B. 
vietnamiensis (86) 
 
Gene regulation, ECF 
subfamily 
BDAG_00993 Glucoamylase 3 ? ZP_02893540.1: B. ambifaria (99) Glycoside hydrolase 
 
Genes previously implicated in pathogenesis 
      
BDAG_02781 Ribosomal protein L4 14 Antibiotic resistance rpl4 Macrolide resistance 
BDAG_02180 DNA gyrase subunit A 11 Antibiotic resistance gyrA 
Quinolone resistance 
(see Figure 3A) 
BDAG_03694 Beta-lactamase 8 Antibiotic resistance 
YP_001811541.1: B. ambifaria 
(99), bla1: B. cereus (88) Beta-lactam resistance 
BDAG_04506 ABC-type multidrug transport system ATPase and permease components 5 
Antibiotic 
resistance mdlB: M. succiniciproducens (95) 
Hypothetical role in AB 
resistance 
BDAG_00220 Type IIA topoisomerase 3 Antibiotic resistance gyrB Quinolone resistance 
      
BDAG_02317 Glycosyltransferase 10 Membrane Synthesis wbaD: E. coli (88) (see Figure 3B) 
BDAG_02321 Glycosyltransferase 6 Membrane Synthesis mtfA: A. fulgidus (99) Mannitol transferase 
BDAG_01250 Major facilitator superfamily (MFS_1) transporter 3 
Membrane 
Synthesis lplT: B. cenocepacia (99) 
Lisophospholipid 
transporter 
BDAG_00856 hypothetical protein 3 Membrane Synthesis 
YP_002231781.1: B. cenocepacia 
(99), lptG: E. clocae (93) 
Permease YjgP/YjgQ 
family 
      
BDAG_03003 Large exoprotein involved in heme utilization or adhesion 4 Secretion 
ZP_02889734: B. ambifaria (97), 
fhaB: P. ananatis (80) Secreted product 
BDAG_00179 Type II secretory pathway component PulD 3 Secretion gspD: B. cenocepacia (99) 
Secretion system 
component 
 
Broad annotations are automatically assigned in the reference genome. Most relevant known homologs, 
additional annotation, and biological relevance were determined by manual annotation.  
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Table S1.3: Primers used in this study 
Name Primers 5’->3’ 
GlycTcompF TTTTTGAGCTCATACGACGTCGATGCCGGAGATCG 
GlycTcompR TTTTTTCTAGACCGTCGCTCCGGAGTCTCAACC 
pUCP18up GGCTCGTATGTTGTGTGGAATTGTGAGCGG 
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Supplementary Information 1 
 
Burkholderia dolosa 
Burkholderia dolosa is a member of the Burkholderia cepacia complex, a group of 
related species capable of infecting immune-compromised hosts. Members of the B. 
cepacia complex were initially categorized as Pseudomonas cepacia. Members of this 
complex are found frequently in the soil, and are associated with the roots of plants (they 
were first identified as the cause of onion rot in 1950). 
However, in the 1980s they were recognized as an emerging cause of infection in 
patients with cystic fibrosis1. Some members of the B. cepacia complex, including B. 
dolosa, cause deadly ‘cepacia syndrome’ – a rapid health decline characterized by 
fevers, necrotizing pneumonia and bacteremia (presence of bacteria in the 
bloodstream)2. 
B. dolosa is one of the rarest members of the B. cepacia complex. It was first 
established as a distinct species in 20043. 
Patient cohort 
We retrospectively studied a small epidemic of Burkholderia dolosa that affected 39 
people with cystic fibrosis (CF) who were treated at a Boston hospital. The average age 
of these patients at date of first B. dolosa detection was 19 years. 
Treatment of these patients for B. dolosa and other bacterial infections of CF patients 
includes frequent administration of antibiotics, usually in combination4. While antibiotics 
are often helpful in quelling an acute flare-up, they are generally ineffective in eradicating 
the infection. Of the 34 patients who continued care at the Boston hospital, only 3 
eventually cleared the infection. Some of the patients still colonized remain 
asymptomatic, while others developed cepacia syndrome5. At the time of submission, 9 
patients had received lung transplants; 17 patients had died, all but one from their 
illness.  
We chose to study 14-deidentified patients, including patient zero of the epidemic. 
Seven patients were included in this study on the basis of availability of isolates from the 
blood; the remaining six were chosen at random among patients who did not have 
bacteremia. At the time of writing, 5 of these patients had received lung transplants; 8 
patients had died, all but one from their illness. None of these patients cleared their 
airways of Burkholderia dolosa. 
As mentioned above, these patients receive frequent antibiotic therapy. However, the 
patients’ records do not allow us to know their history of antibiotic usage with high 
enough accuracy to correlate this data with antibiotic-resistance or data related to 
antibiotic-resistance. 
Bacterial isolate collection 
Samples from these patients were collected during normal care. The 97 isolates labeled 
“airways” were obtained from either sputum or bronchoalveolar lavage (BAL) fluid. 
Another 11 isolates labeled “blood” were sampled from the blood cultures. The 
remaining 4 isolates labeled “other” were sampled from pleural tissue pleural or 
mediastinal tissue from fluid obtained during surgical procedures. Details are in Table 
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S1.1. In most cases, the frozen clinical stocks were prepared from a single colony. The 
timing between isolates is described in Figure S1.1. 
Frozen clinical stocks were streaked on solid media. A single colony from each plate 
was chosen at random and frozen in 15% glycerol to create a working library. 
We also obtained the isolate LMG18943 (also known as AU0645), shown elsewhere to 
be of the same strain6 (Strain SLC6). This isolate was taken from a different CF patient 
in a different location in the USA during the duration of the epidemic. We used this 
isolate as the outgroup for phylogenetic analyses.  
Throughout this work, time of isolation is reported relative to the collection of an isolate 
from patient zero (isolate A-0-0). The time of collection of this isolate is unrelated to the 
first detection of B. dolosa in this patient. Letters distinguish isolates collected on the 
same month from the same patient. In some cases, the lettering is not continuous; some 
sequenced isolates were omitted from the study because they were either duplicates or 
recovered during autopsy. 
Illumina sequencing 
DNA was extracted from single colonies using standard procedures, following 
instructions from MoBio UltraClean® Microbial DNA Isolation Kit (cat # 12224-50, MO 
BIO Laboratories, Inc., USA).  
Genomic libraries were constructed using the Illumina-compatible NexteraTM DNA 
Sample Prep Kit (cat# GA091120, EPICENTRE Biotechnologies, USA). Each genomic 
library was made up of four to six multiplexed genomes, barcoded with NexteraTM 
adapters. The libraries were sequenced using single-end, 75 bp reads on Illumina 
Genome Analyzer GAII by Partners HealthCare Center for Personalized Genetic 
Medicine (PCPGM). On average, 4.6 million reads were obtained per isolate (Figure 
S1.2a).  
Reads were aligned using the B. dolosa genome AU0158 as a reference7; this reference 
genome belongs to an isolate recovered from patient zero. The reference genome is 
6.42 megabases (Mb) long and comprises 3 chromosomes of lengths 3.41 Mb, 2.18 Mb, 
and .83 Mb. Alignment was performed by PCPGM using the standard Illumina pipeline8 
(CASAVA v1.6). We used SAMtools 0.1.12a to manipulate consensus sequences and 
find SNP between isolates9. !
For each strain we calculated the average number of reads aligned to each position in 
the reference genome (Figure S1.2b). We found the average read depth to be 37x. 
These reads produced high coverage: on average we obtained confident calls for 93% of 
the genome (Phred score>25).!
Polymorphic loci between the 112 isolates 
We first obtained the list of 4,375 loci where at least one of the 113 isolates (including 
the outgroup) was different than the reference genome. Next, we filtered out data to 
obtain a high-quality list of 511 polymorphic loci, where we expect less than one false 
positive. 
Specifically, we used a two-step process.  First, we retained loci where polymorphism 
was observed between at least two strains called with high confidence scores (Phred 
score >35). Then, at each of these 511 loci, we included all calls that were made with 
high enough confidence (Phred score >25; because fewer calls were made compared 
with the previous list, the Phred score could be lowered). !
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With this procedure, we obtain 56,811 calls at these 511 polymorphic loci. This two-step 
process and choice of scores maximizes the number of isolates with information per 
location, under the constraint of obtaining at most one miscalled base among all 56,811 
calls.  On average, 111 out of 113 isolates were called at these loci.  
19 of these loci are unique to the outgroup; we resolve 492 polymorphic loci within the 
isolates of this epidemic. 
Intragenic bias 
We calculated that 426 of the 561 mutations occurred in intragenic regions (using the 
5012 genes automatically annotated on the reference genome): the proportion of 
intragenic mutations is 75% (95% CI=72%-79%, Clopper-Pearson binomial confidence). 
This estimate is not statistically distinct from the intragenic proportion of the B. dolosa 
genome (79%): we do not detect a significant intragenic bias (p=0.04, binomial sampling 
with n=561). 
Strains used for O-antigen assay 
The strains used in the O-antigen assay presented in Figure 2.3b were (from left to 
right): A-0-0, AU0158, M-9-4, G-9-8, G-9-11b, C-12-1, B-11-1, E-9-5, E-12-1, C-10-0, K-
10-0, K-12-5, K-12-8a-$, F-6-9, I-9-6, N-12-1, J-13-6a-$, J-14-2, J-14-8, and J-12-4. 
Glycosyltransferase complementation 
Escherichia coli Sm1010 and B. dolosa were routinely grown on Luria agar (LA) 
containing 1.5% Bacto Agar (Difco, Franklin Lakes, N.J.). The medium was 
supplemented with 10 µg of tetracycline per ml for E. coli and 75 µg of tetracycline and 
100µg of ampicillin per ml for B. dolosa, as appropriate. The glycosyltransferase gene 
BDAG_02317 was amplified by PCR with primers GlycTcompF and GlycTcompR (see 
Table S3.5) and genomic DNA of B. dolosa AU0158. This gene was ligated into the 
broad-host-range vector pUCP18Tc creating expression plasmid pUCP18Tc-GlycT. 
Biparental matings were performed to transfer pUCP18Tc-GlycT from E. coli SM10 to B. 
dolosa as previously described11. Transconjugants were confirmed by PCR using a 
forward primer specific of the complementing plasmid (pUCP18up) and primer 
GlycTcompR. O-antigen presentation was assayed as described in Online Methods. 
fix genes  
Burkholderia dolosa lacks the genes necessary for nitrogen fixation1 suggesting that the 
fix system is utilized for gene-regulation of a different nature, as has been seen in other 
species12. All of the 24 mutations seen in this pathway are nonsynonymous and none 
result in a stop codon, suggesting a tuning of the pathway rather than its interruption. For 
this reason, we annotate these genes as involved in oxygen-related gene regulation. 
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 Appendix 2:  
Supplemental Materials for Genetic variation of a bacterial 
pathogen within individuals with cystic fibrosis provides a 
record of selective pressures (Chapter 3) 
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Figure S2.1: Some fixed mutations may have arisen and fixed prior to patient 
colonization. (a) Number of patient-specific and shared fixed mutations per patient. Shared 
fixed mutations are found to be fixed in some, but not all sputum samples, while patient-
specific mutations are fixed in only one patient’s sample. (b) The fixed mutations for each 
patient define a patient LCA, and we generate a maximum parsimony phylogeny among 
patient LCAs. The presence of interior branches in this phylogeny illustrates that some 
shared fixed mutations likely arose in an LCA of multiple patients. This tree was generated 
using the dnapars package in Phylip1 and visualized in Figtree. !
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Figure S2.2:  Excess mutations in Patient 5 are due to hypermutation. (a) Polymorphic 
mutations found within each patient’s population were classified into 6 categories, without regard 
for strand (e.g. A->C is equivalent to T->G). P5 has an excess of both types of transition 
mutations (P<.001, Grubb’s test for outliers) but not transversion  (P<.001, Grubb’s test for 
outliers) mutations, consistent with the known spectrum of mutations caused by mutL defects. (b) 
We scanned the annotations of the genes with point mutations in P5 for “DNA’” and manually 
inspected the results for roles in DNA repair. Only BDAG_02407 met this criteria. An NCBI BLAST 
search revealed this as a homolog of mutL, an essential component of mismatch repair. Other 
mutL sequences from NCBI gene were aligned and conservation was calculated using CLC 
Sequence Viewer 6. (c) P5’s population has an increased relative rate of synonymous mutations. 
dN/dS was assessed as listed in the Methods for the intragenic mutations found in P1-P4 (non-
hypermutators, n=278) and the intragenic  mutations found in P5 (n=242). As described in the 
Methods, our approach for dNdS accounts for the decreased expected N/S in the hypermutators. 
Gray bars indicate 95% confidence interval. P < .001, one-side binomial z-test comparing the 
observed to the N/S expected under a dN/dS of 2.5 (P1-P4) and P5’s spectrum of mutations.!
BDAG_02407: mutL homolog  
Conservation 
0 100 
L54P b!
a!
AT−>TA AT−>CGGC−>CG GC−>TA AT−>GC GC−>AT
0
20
40
60
80
100
120
140
Nu
m
be
r o
f S
NP
s
Nu
m
be
r o
f p
ol
ym
or
ph
ic
 m
ut
at
io
ns
 
Transversions 
A-T 
 
T-A 
A-T 
 
C-G 
G-C 
 
C-G 
G-C 
 
T-A 
A-T 
 
G-C 
G-C 
 
A-T 
Transitions 
P1 
P2 
P3 
P4 
P5 
c!
P1−P4 P5
1
2
4
dN
/d
S 
101
Figure S2.3: Search for operon and pathways undergoing parallel evolution within 
patients. We expanded our search for selective pressures to the operon and pathway levels, 
applying the same requirements of multiple mutations and more than one mutation per 2000 
bp. (a) Multiple operons have this multi-diverse signature for selection in each patient (blue 
bars), while under neutrality we expect none in Patients 1-4 (P1-4). In P1-P4, the observed 
number of operons with multiple mutations is greater than the number obtained in > 
995/1000 simulations (white bars show the results of 1000 simulations). For most of the 9 
operons, the mutations that triggered their identification were all concentrated in a single, 
previously identified gene. The operons not previously implicated are shown in Table S2.3 (b) 
We did not find enrichment at the pathway level, suggesting that parallel evolution primarily 
acts at or below the gene level and supporting the idea that binning over larger regions of the 
genome can dilute the signal for selection. For each patient, we observe multiple mutations 
in the same pathway in over 18% of simulations (white bars). Relaxation of the requirement 
of mutations per bp in pathway brings up more multiply mutated genes in the simulations and 
not many more pathways. The two pathways multiply mutated per 2000 bp contain genes 
already found at the gene and operon level. "
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Figure S2.4: Colony re-sequencing from Patient 1 indicates within-patient parallel 
evolution. Seven genes within Patient 1 showed a multi-diverse signature for selection in the 
colony re-sequencing approach. The gene names are listed at top (see Tables S2.2 and 
S2.3) and the phylogeny of 29 colony isolates from Patient 1 is shown at left (same as Figure 
2.3a). For each isolate, any mutations found in that gene are indicated on the corresponding 
horizontal line and column. No isolate has multiple mutations in the same gene. !
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Figure S2.5: Deep population sequencing indicates within-patient 
parallel evolution. Individual short reads were used to analyze the 
linkage between nearby polymorphisms and to categorize each read as 
supporting the ancestral genotype (WT), a single mutant, or the double 
mutant (DM). The percentage of reads supporting each case is shown. In 
total, we found 11 cases where multiple polymorphisms were close 
enough on the genome to asses linkage using the same 50 base-pair 
read (2 cases shown in Figure 2.5c-d). Patient, gene annotation, 
homologous gene name, and number of reads overlapping both loci are 
shown for each case. Only one case supports a double mutant; this 
intergenic region does not have any single mutants.  "
P2: Transcription factor 
(BDAG_01528) n=17"
P5:Transcriptional regulator 
(BDAG_00466) n=58"
P4: Intergenic region 
upstream of transcriptional 
regulator (BDAG_01614) 
n=685"
P4: Intergenic region 
upstream of catJ 
(BDAG_04188) n=267"
P2T: Glycosyltransferase 
wpbX (BDAG_02321) 
n=574"
P3: Intergenic region 
upstream of peroxiredoxin 
lsfA (BDAG_02383) n=953"
P1: Intergenic region 
upstream of secreted 
protein (BDAG_00733) 
n=644"
P4: Intergenic region 
upstream of secreted 
protein (BDAG_00733) 
n=558"
P4: sigma subunit rpoD 
(BDAG_02877) n=69"
Pe
rc
en
t o
f r
ea
ds
 s
up
po
rti
ng
 
 
104
P2 P2T P1 P3 P4
0
5
10
15
20
25
Average years to patient LCA (?p)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Day 0 Mutation Allele Frequency
Da
y 0
 M
ut
at
ion
 A
lle
le 
Fr
eq
ue
nc
y
S14
Figure S2.6: Comparison between two samples from same patient taken 14 days apart. 
(a) Scatter plot of mutant allele frequencies between samples shows agreement at very 
diverse positions with more variation in lower frequency mutations. (b) Both samples give 
similar estimates for time to patient LCA. See Supplementary Information 2 for discussion of 
error. (c) Three genes show a multi-diverse signature for selection in both samples, and each 
sample has only one gene displaying this signature that is not present in the other sample. 
Moreover, these two sample-specific genes show abundant mutations at both time points. 
See Methods for a description of the the two samples taken from this patient.!
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Figure S2.7: Deep population sequencing has low false positive rate and higher false 
negative rate. (a) We compared our approaches by mixing 20 isolates in silico, taking the 
same number reads from each of 20 isolates. We performed population deep sequencing 
analysis on this mixture of single-end reads, using the same isogenic control without paired-
end information. All positives in the deep sequencing that were also found in the single 
colony isolates (no false positives). False negative positions (blue circles) fail the strand-bias 
filter or other quality filters (not shown). Jitter is added on the X-axis to improve visibility. (b) 
The proportion of positions called in the isolates not called in the in silicio deep sequencing 
(false negatives). 91% of positions called in the isolates were also called in deep sequencing 
(black circles). !
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Figure S2.8: Paired-end information and Nextera amplification do not significantly affect 
polymorphism detection. (a) To investigate the effect of paired-end information on our results, 
we re-ran all population deep sequencing analyses, treating each read from a pair independently. 
For each genomic position, the mutation frequency from each approach is shown. Gray circles 
indicate positions called by both methods, blue circles indicate positions that did not pass all filters 
in the paired approach and red circles, and red circles indicate positions that did not pass all filters 
in the unpaired approach. 94% of positions called in the paired approach are also called in the 
unpaired approach and 98% of reads called in the paired approach are called in the paired 
approach. Bowtie2 sometimes fails to align unpaired reads well near short indels, and these 
positions have low coverage in the unpaired approach. Consistent with the fact that the paired 
approach discards pairs of reads when only one of the reads has poor sequencing quality 
(Illumina provided Phred scores), most of the discrepancy is attributable to noise around 
thresholds. The list of genes under selection within patients is identical using both approaches. (b) 
To understand the maximum possible frequency of errors introduced early during the 9-cycle PCR 
step of Nextera preparation, we performed simulations of PCR (described in Supplementary 
Information 2). Each simulation represents a unique single-nucleotide genomic position, and we 
ran 1 million simulations for each of 3 values of initial templates. We plot the histograms of final 
mutation frequency after 9 cycles for all genomic positions on a log scale (simulations with no 
mutations are not shown)."
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!Table S2.4: Coverage statistics 
Sample Type of reads 
Percent of 
filtered reads 
aligned 
Percent of 
reference genome 
callable* 
Average 
coverage 
Isogenic 
control 50bp paired end 94.8% 93.2% 708 
P1 50bp paired end 96.3% 91.3% 582 
P2 50bp paired end 95.3% 89.5% 489 
P2T 50bp paired end 96.1% 90.7% 509 
P3 50bp paired end 95.9% 89.8% 420 
P4 50bp paired end 95.4% 89.8% 401 
P5 50bp paired end 96.1% 89.1% 323 
P1-01 50bp single end 96.5% 94.8% 36 
P1-02 50bp single end 96.7% 94.7% 37 
P1-03 50bp single end 96.7% 94.4% 34 
P1-04 50bp single end 96.4% 94.7% 23 
P1-05 50bp single end 96.5% 94.8% 37 
P1-06 50bp single end 96.7% 93.3% 43 
P1-07 50bp single end 96.9% 94.7% 51 
P1-08 50bp single end 96.5% 94.8% 26 
P1-09 50bp single end 96.9% 94.7% 40 
P1-10 50bp single end 96.8% 94.4% 40 
P1-11 50bp single end 96.8% 94.8% 60 
P1-12 50bp single end 96.7% 94.8% 28 
P1-13 50bp single end 96.6% 94.8% 36 
P1-14 50bp single end 96.6% 94.4% 32 
P1-15 50bp single end 96.6% 94.8% 29 
P1-16 50bp single end 96.7% 94.7% 40 
P1-17 50bp single end 96.8% 94.8% 48 
P1-18 50bp single end 96.7% 94.7% 39 
P1-19 50bp single end 96.6% 94.7% 25 
P1-20 50bp single end 96.7% 94.8% 26 
P1-21 50bp single end 96.5% 94.7% 34 
P1-22 50bp single end 96.6% 94.7% 36 
P1-23 50bp single end 96.8% 94.7% 48 
P1-24 50bp single end 96.7% 93.4% 38 
P1-25 50bp single end 97.1% 94.7% 39 
P1-26 50bp single end 96.4% 94.6% 32 
P1-27 50bp single end 96.9% 94.8% 37 
P1-28 50bp single end 96.7% 94.8% 40 
P1-29 50bp single end 96.4% 94.7% 25 
*For isolates, callable positions are those with a consensus quality score (FQ, provided by samtools) score below -40. For population 
sequencing, callable positions are those that met coverage, base quality, mapping quality, and tail distance thresholds and for which the 
isogenic control had a major allele frequency of at least 98.5% 
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!Supplementary Information 2 
Sample collection 
Expectorated sputum samples were collected at Boston Children’s Hospital after written informed consent 
was obtained under protocols approved by the Institutional Review Boards at both Boston Children’s 
Hospital and Harvard Medical School. Samples were immediately placed on ice and then liquefied with 
dithiothreitol. 10-15 mL phosphate buffered saline containing 1mM of dithiothreitol was added to each 
sample. Each sample was incubated on ice for 1 hour, vortexing every 20 minutes. 50% glycerol was 
added to each sample to a final concentration of 20%, and samples were then frozen at -80°C. 
Sample prep, colony re-sequencing approach 
Using a sterile 1-microliter plastic loop, ice was scraped from the top of the frozen homogenized sputum 
from Patient 1 and streaked onto the Burkholderia cepacia complex specific media, OFPBL (oxidation-
fermentation basal medium supplemented with polymyxin B, bacitracin, lactose, and agar, BD diagnostic, 
USA). Individual colonies were picked into individual culture tubes containing 10mL of LB. Cultures were 
incubated with shaking at 37° C for 20 hours. Aliquots were stored in 15% glycerol at -80° C for further use. 
1.8mL of this overnight culture was used for genomic DNA extraction.  
Sample prep, deep population sequencing 
Frozen sputum samples were thawed on ice. A 10-fold serial dilution was performed in PBS, and 0.8 mL of 
each dilution was plated on OFPBL using a disposable plastic spreader. Plates were dried and incubated 
at 37°C for 48 hours. Variation in colony size was observed within each sample. This variation may cause 
differences between allele frequencies measured and in vivo allele frequencies. Our results are robust to 
such differences; the signature for selection reported is insensitive to allele frequency (so long as 
mutations are above 3%) and all lineages, both those underrepresented and overrepresented, have been 
accumulating mutations since their LCA according to the molecular clock.  
For each sample, a dilution plate was selected for harvesting which had between 5,000 and 30,000 small, 
mostly non-overlapping colonies. 2 mL of PBS was added and cells were scraped with a plastic loop and 
transferred to a microcentrifuge tube. A 0.5 mL aliquot of each sample was stored in 15% glycerol at -80°C 
for future use, and the remainder was used for DNA extraction. For the isogenic control, the same 
procedure was used, starting the serial dilution from a colony taken from Patient 1’s sputum sample. 
Initial data processing workflow for colony re-sequencing 
We used custom MATLAB scripts to pipe together cutadapt24 (remove adapter read-through), sickle25 (trim 
low quality bases from reads), bowtie226 (align reads), and SAMtools27 (call potential variants) and run 
them in parallel for many isolates on the Orchestra shared research cluster at Harvard Medical School. The 
following options were used: 
> cutadapt -a CTGTCTCTTATACACATCTCTGA reads_1.fastq > trimmed_reads_1.fastq 
> sickle se -f trimmed_reads_1.fastq -o filtered_reads_1.fastq  -s singles.fastq -q 20 -l 25 
> bowtie2 -X 2000 --no-mixed --very-sensitive --n-ceil 0,0.01 --un-conc unaligned.fastq -x 
refgenome_bowtie2  -U filteredreads.fastq -S aligned.sam  
> samtools view -bS -o aligned.bam aligned.sam 
> samtools sort aligned.bam aligned.sorted 
> samtools mpileup -q30 -S -ugf refgenome.fasta aligned.sorted.bam > sample 
> bcftools view -g sample > sample.vcf 
> bcftools view -vS sample.vcf > variant.vcf 
Mutations were called using custom MATLAB scripts and the vcf files. 
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!Initial data processing workflow for deep population sequencing 
We used custom MATLAB scripts to pipe together cutadapt, sickle, bowtie2, and SAMtools and run them in 
parallel for many isolates on the Orchestra shared research cluster at Harvard Medical School. The 
following options were used: 
> cutadapt -a CTGTCTCTTATACACATCTCTGA reads_1.fastq > trimmed_reads_1.fastq 
> cutadapt -a CTGTCTCTTATACACATCTCTGA reads_2.fastq > trimmed_reads_2.fastq 
> sickle pe -f trimmed _reads_1.fastq -r trimmed _reads_2.fastq -o filtered_reads_1.fastq -p 
filtered_reads_2.fastq -s singles.fastq -q 20 -l 50 
> bowtie2 -X 2000 --no-mixed --very-sensitive --n-ceil 0,0.01 --un-conc unaligned.fastq -x 
refgenome_bowtie2  -1 filteredreads_1.fastq -2 filteredreads_2.fastq -S aligned.sam  
> samtools view -bS -o aligned.bam aligned.sam 
> samtools sort aligned.bam aligned.sorted 
> samtools mpileup -q30 -s -O -B -d3000 –f refgenome.fasta aligned.sorted.bam > sample.pileup 
> samtools mpileup -q30 -S -ugf refgenome.fasta aligned.sorted.bam > sample 
> bcftools view -g sample > sample.vcf 
> bcftools view -vS sample.vcf > variant.vcf 
The strict removal of all trimmed reads in sickle (-l 50 option) was used to make comparing tail distances 
across reads comparable. Custom MATLAB scripts were used to call diverse positions using the 
sample.pileup file. Fixed positions were called using custom MATLAB scripts and the vcf files.  
 
Polymorphic mutation calling (deep population sequencing) 
Using our isogenic control as a negative control, multiple isolates from Patient 1 as a positive control, and 
an interactive MATLAB environment that enabled investigation of the raw data, we developed a set of 
filters to identify polymorphic positions with minor allele frequency above 3%. We set the thresholds for 
these filters conservatively, minimizing false positives. An in silico mixing of reads from the isolates calls no 
positions not detected in the isolates and calls 78% of positions found when treating isolates separately 
(Figure S2.7). Similarly, 85.6% of positions called polymorphic above 3% frequency in Patient 1 using the 
pooled approach were also detected in the isolates (compared to 91.5% expected due to binomial 
sampling). No position is detected at greater than 13.5% frequency in population sequencing that is not 
detected in the isolates. All fixed and polymorphic mutations found and their frequencies are listed Table 
S2.6. 
We considered a position to be polymorphic if it met the following quality thresholds in the given sample: 
• Minor allele frequency: More than 3% of reads support a particular minor allele 
• Overall coverage: At least 15 reads align in both the forward and reverse direction, and the total 
number of reads aligning is below the 99th percentile of covered positions in that sample.   
• Minor allele coverage: At least 3 reads per major and minor allele aligning in both the forward and 
reverse direction (4 thresholds: forward minor, forward major, reverse minor, reverse major) 
• Base quality: Average base quality (provided by sequencer) of greater than 19 for both the major 
and minor allele calls on both the forward and reverse strand 
• Mapping quality: Average mapping quality (provided by aligner) of greater than 34 for reads 
supporting both the major and minor allele on both the forward and reverse strand 
• Tail distance: Average tail distance of between 6 and 44 for reads supporting both the major and 
minor allele on both the forward and reverse strand 
• Indels: Fewer than 20% of the reads aligning to that position support an indel at any position along 
that read 
• Strand bias: A P-value of > 10-5 supporting a null hypothesis that the minor allele frequency is the 
same for reads aligning to both the forward and reverse strand (Fisher’s exact test). 
• Tail distance bias: P-values of > 10-5 supporting null hypotheses that the tail distances come from 
the same distribution for both the minor and major allele, for both the forward and reverse strand (t-
test)    
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!• Isogenic control: More than 98.5% of reads aligning to this genomic position in the isogenic 
control support a major allele 
 
These filters remove false positive polymorphisms, which are not caused by randomly distributed 
sequencing error, but by systematic errors at particular genomic positions. For example, false positive 
polymorphisms can occur from misalignment near small insertions and deletions, from recent duplications 
represented once in the reference genome, and from neighboring sequences that increase the probability 
of sequencing error. Most systematic errors have hallmarks in individual reads data. Errors induced by a 
particular nearby DNA sequence, for example, will produce polymorphism on reads aligning in either the 5’-
>3’ or 3’->5’ direction, but not both. We do not consider regions with very high coverage, which may reflect 
recent or older duplications that are only listed once in the draft genome. We use the paired end 
information only to discard discordant read pairs and find that we would get similar results even without this 
information (see Figure 3.8a).   
We find that false positive polymorphisms tend to be repeatable, showing nearly identical frequency and 
nucleotide identity across samples. Some genomic positions show repeatable polymorphism across 
samples and our isogenic control despite not having a hallmark for false-positive in the individual read 
data; such positions are removed by the requirement that the position be isogenic in the isogenic control 
(10-15 genomic positions per sample). 
Estimation of false-positives from PCR amplification 
While the Nextera kit involves PCR amplification, the large amount of template used and the limited 
number of cycles should prevent errors from PCR amplification from reaching near the 3% minor allele 
frequency threshold. We used two approaches to demonstrate this: 
Simulation: To understand the maximum possible frequency of errors introduced early during the 9-cycle 
PCR step of Nextera preperation, we performed simulations of PCR. We conservatively assume that all 
PCR errors create the same mutated nucleotide, we assume perfect amplification, and we model a single 
genomic position (nucleotide) at a time. We assume a uniform error rate across the genome of 3.3 *10-7 
(provided by Epicentre). During each cycle of the simulation, new mutated molecules are introduced 
according to a Poisson process, the number of molecules doubles, and the number of previously mutated 
molecules doubles. We simulate 3 different values for the number of initial molecules covering each 
nucleotide. More initial molecules will buffer PCR errors. Given that the final concentration of DNA from the 
PCR reaction is 300ng and the genome size is 6.4 Mb, even coverage and perfect amplification predicts 
that there are 8.7x104 copies of each nucleotide in the initial pool (following tagmentation). Because 
genomic positions are certainly not represented evenly in this initial pool, we ran sets of simulation 
simulations using 104, 103, and 102 initial molecules (regions with lower abundances will not meet coverage 
requirements in final library). For each number of initial molecules, we simulate 106 nucleotide positions, a 
number larger than the number genomic positions with low representation in the initial pool. We find the 
maximum final frequency of mutation in 106 simulations with 102 initial molecules is .1%, much below our 
detection threshold of 3%. Simulations with more starting molecules have even lower error. See Figure 
S2.9b. 
Empirical analysis of isogenic control: We have also empirically estimated less than 1 false positive 
polymorphic genomic position per sample introduced by PCR error per sample. In the isogenic control, 
positions introduced by PCR error will not be filtered out by the quality filters described above (all filters 
except the isogenic control filter). Thus, if PCR introduces false polymorphisms, we should see them in the 
isogenic control. 10 genomic positions in the isogenic control pass all quality filters. Of these 10, 9 show 
consistent polymorphism identity and frequency across all, indicating that when PCR error emerges, 
reproducibility of this PCR error allows it to be filtered out by the isogenic control.  
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!Genetic distance to LCA calculation (deep population sequencing) 
Here, we show that the average number of mutations per cell in a population is equivalent to the sum of the 
mutation frequencies in that population. The number of mutations in a given cell can be represented as !!!! , where ! is the number of positions on the genome, and !! = 1 if a cell as a mutation at position !!and !! = 0 otherwise. Thus: Number!of!muations!per!cell >= ! !!!!!!  
Now, we consider a population of ! cells. The presence of a mutation at position ! in a cell ! is now 
indicated by !!! = 1.  
!!!!!! = !!"!!!!!!!! ! = !!"!!!!!!!! ! = !!"!!!!!
!
!!! = !!
!
!!!  
Where !! is the mutation frequency at position ! on the genome.  
 
Error sources in estimation of time to LCA 
Potential sources of error in estimating the time to LCA include Poisson error in the number of mutations 
accumulated in each lineage since the LCA, underestimation due to limited sensitivity in detecting 
mutations, overestimation due to false positives, and underestimation due to incomplete sampling of the 
diversity in the lung. Additionally, possible errors in converting <dLCA> to years include potential 
overestimation of the molecular clock resulting in underestimation of time to LCA (if historical sampling in 
the clinic is biased towards colonies with faster growth rates) and deviations from clock-like evolution (e.g. 
extra doublings following antibiotic treatment). The confidence intervals of time to LCA presented for the 
colony re-sequencing approach are calculated according to a Poisson distribution. We assume that the 
number of mutations in each cell is drawn from a Poisson distribution with λ equal to the mean across 
cells. Poisson measurement error is minimal for the population sequencing, as we are sampling hundreds 
of lineages simultaneously. The differences in estimated time to LCA between the two samples taken from 
Patient 2 are larger than would be expected given only Poisson error, suggesting other factors contribute to 
our ability to date the LCA (Figure S2.6b). 
Gene annotation  
Genes were annotated using a suite of online bioinformatics tools. Open reading frames were compared to  
RefSeq using NCBI’s BLASTp and close homologs were scanned for gene names. For genes for which 
this did not indicate an obvious homolog, the Burkholderia Genome Database28 and Microbial Genome 
Database for Comparative Analysis29 (MBGD) were used to probe for candidate ortholog gene names and 
look for synteny (As B. dolosa is not in MBGD, homologs from other members of the B. cepacia complex 
were used to query MBGD).  
When these searches produced candidate orthologs, reverse BLAST was used to test the orthology30; an 
ORF with that putative ortholog name from E. coli or other well-described non-Burkholderia genome was 
located in the NCBI gene database and used as a query for Blastp against the B. dolosa genome. If the 
original query came up as the best match and had an E value of < .001, this ortholog name was listed in 
Figure 3.5e. Otherwise, the number of the locus tag was listed. Biological relevance was assigned using 
literature search and various databases, including WikiGenes31, STRING32, UniProt33, and PATRIC18. 
Subcellular localization was predicted using CELLO2. Literature searches were conducted to determine 
functional role of genes. Summary and gene-specific references can be found in Tables S2.2-3. 
Visualization for Figure 3.5e was performed using Cytoscape34.  
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